<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Acute myeloid leukemia,Hematology,Featured articles,Hematology,1827,1845,1856,1877,1879,1889,1900" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Acute myeloid leukemia - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Acute myeloid leukemia</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <table class="infobox" style="width: 200px; font-size: 95%; text-align: left;">
<caption style="background: lightgrey; font-size: 95%;"><b>Acute myeloid leukemia</b><br />
<i>Classification &amp; external resources</i></caption>
<tr>
<th colspan="2" style="text-align: center; font-size: smaller;">
<div class="center">
<div class="floatnone"><span><a href="../../../a/u/e/Image%7EAuer_rods.PNG_6e03.html" class="image" title=""><img src="../../../upload/thumb/d/d8/Auer_rods.PNG/190px-Auer_rods.PNG" alt="" width="190" height="177" longdesc="../../../a/u/e/Image%7EAuer_rods.PNG_6e03.html" /></a></span></div>
</div>
</th>
</tr>
<tr style="line-height: 1;">
<td colspan="2" style="text-align:center;"><small>Bone marrow aspirate showing acute myeloid leukemia. Arrows indicate <a href="../../../a/u/e/Auer_rods.html" title="Auer rods">Auer rods</a>.</small></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-10_codes_1183.html" title="List of ICD-10 codes">10</a></th>
<td><a href="../../../i/c/d/ICD-10_Chapter_C_7ba1.html" title="ICD-10 Chapter C">C</a><a href="http://www.who.int/classifications/apps/icd/icd10online/?gc81.htm+c920" class="external text" title="http://www.who.int/classifications/apps/icd/icd10online/?gc81.htm+c920" rel="nofollow">92.0</a></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-9_codes_cdaa.html" title="List of ICD-9 codes">9</a></th>
<td><a href="http://www.icd9data.com/getICD9Code.ashx?icd9=205.0" class="external text" title="http://www.icd9data.com/getICD9Code.ashx?icd9=205.0" rel="nofollow">205.0</a></td>
</tr>
<tr>
<th><a href="../../../i/n/t/International_Classification_of_Diseases_for_Oncology_3a4e.html" title="International Classification of Diseases for Oncology">ICD-O:</a></th>
<td><a href="../../../i/c/d/ICD-O_d226.html" title="ICD-O">M</a><a href="http://www.progenetix.net/~pgscripts/progenetix/I98613/casetable.html" class="external text" title="http://www.progenetix.net/~pgscripts/progenetix/I98613/casetable.html" rel="nofollow">9861/3</a></td>
</tr>
<tr>
<th><a href="../../../o/m/i/OMIM_6457.html" title="OMIM">OMIM</a></th>
<td><a href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602439" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602439" rel="nofollow">602439</a></td>
</tr>
<tr>
<th><a href="../../../d/i/s/Diseases_Database_9859.html" title="Diseases Database">DiseasesDB</a></th>
<td><a href="http://www.diseasesdatabase.com/ddb203.htm" class="external text" title="http://www.diseasesdatabase.com/ddb203.htm" rel="nofollow">203</a></td>
</tr>
<tr>
<th><a href="../../../e/m/e/EMedicine_a89c.html" title="EMedicine">eMedicine</a></th>
<td><a href="http://www.emedicine.com/med/topic34.htm" class="external text" title="http://www.emedicine.com/med/topic34.htm" rel="nofollow">med/34</a>&#160;</td>
</tr>
</table>
<p><b>Acute myeloid leukemia</b> (<b>AML</b>), also known as <b>acute myelogenous leukemia</b>, is a <a href="../../../c/a/n/Cancer.html" title="Cancer">cancer</a> of the <a href="../../../m/y/e/Myeloid.html" title="Myeloid">myeloid</a> line of <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">white blood cells</a>, characterized by the rapid proliferation of abnormal cells which accumulate in the <a href="../../../b/o/n/Bone_marrow.html" title="Bone marrow">bone marrow</a> and interfere with <a href="../../../h/a/e/Haematopoiesis.html" title="Haematopoiesis">the production of normal blood cells</a>. AML is the most common <a href="../../../a/c/u/Acute_leukemia.html" title="Acute leukemia">acute leukemia</a> affecting adults, and its incidence increases with age. While AML is a relatively rare disease overall, accounting for approximately 1.2% of cancer deaths in the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a>,<sup id="_ref-cancerstats_0" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup> its incidence is expected to increase as the population ages.</p>
<p>The symptoms of <b>AML</b> are caused by replacement of normal bone marrow with leukemic cells, resulting in a drop in <a href="../../../r/e/d/Red_blood_cell.html" title="Red blood cell">red blood cells</a>, <a href="../../../p/l/a/Platelet.html" title="Platelet">platelets</a>, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. While a number of risk factors for AML have been elucidated, the specific cause of AML remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal in weeks to months if left untreated.</p>
<p>Acute myeloid leukemia is a potentially curable disease; however, only a minority of patients are cured with current therapy. AML is treated initially with <a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">chemotherapy</a> aimed at inducing a <a href="../../../r/e/m/Remission_%28medicine%29.html" title="Remission (medicine)">remission</a>; some patients may go on to receive a <a href="../../../s/t/e/Stem_cell_transplant.html" title="Stem cell transplant">hematopoietic stem cell transplant</a>.</p>
<p>Areas of active research in acute myeloid leukemia include further elucidation of the cause of AML; identification of better prognostic indicators; development of new methods of detecting residual disease after treatment; and the development of new drugs and <a href="../../../t/a/r/Targeted_therapy.html" title="Targeted therapy">targeted therapies</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Symptoms"><span class="tocnumber">2</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-1"><a href="#Causes"><span class="tocnumber">3</span> <span class="toctext">Causes</span></a></li>
<li class="toclevel-1"><a href="#Epidemiology"><span class="tocnumber">4</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1"><a href="#Pathophysiology"><span class="tocnumber">5</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1"><a href="#Diagnosis"><span class="tocnumber">6</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-1"><a href="#Classification"><span class="tocnumber">7</span> <span class="toctext">Classification</span></a>
<ul>
<li class="toclevel-2"><a href="#French-American-British_classification"><span class="tocnumber">7.1</span> <span class="toctext">French-American-British classification</span></a></li>
<li class="toclevel-2"><a href="#World_Health_Organization_classification"><span class="tocnumber">7.2</span> <span class="toctext">World Health Organization classification</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Prognosis"><span class="tocnumber">8</span> <span class="toctext">Prognosis</span></a>
<ul>
<li class="toclevel-2"><a href="#Cytogenetics_and_prognosis_in_AML"><span class="tocnumber">8.1</span> <span class="toctext">Cytogenetics and prognosis in AML</span></a></li>
<li class="toclevel-2"><a href="#Antecedent_MDS_and_prognosis"><span class="tocnumber">8.2</span> <span class="toctext">Antecedent MDS and prognosis</span></a></li>
<li class="toclevel-2"><a href="#Other_prognostic_markers"><span class="tocnumber">8.3</span> <span class="toctext">Other prognostic markers</span></a></li>
<li class="toclevel-2"><a href="#Overall_expectation_of_cure"><span class="tocnumber">8.4</span> <span class="toctext">Overall expectation of cure</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Treatment"><span class="tocnumber">9</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2"><a href="#Induction"><span class="tocnumber">9.1</span> <span class="toctext">Induction</span></a></li>
<li class="toclevel-2"><a href="#Consolidation"><span class="tocnumber">9.2</span> <span class="toctext">Consolidation</span></a></li>
<li class="toclevel-2"><a href="#Relapsed_AML"><span class="tocnumber">9.3</span> <span class="toctext">Relapsed AML</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">10</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#Notes"><span class="tocnumber">11</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">12</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">13</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>The first published description of a case of leukemia in the medical literature dates to <a href="../../../1/8/2/1827.html" title="1827">1827</a>, when a French physician named <a href="../../../a/l/f/Alfred-Armand-Louis-Marie_Velpeau_0678.html" title="Alfred-Armand-Louis-Marie Velpeau">Alfred-Armand-Louis-Marie Velpeau</a> described a 63-year-old florist who developed an illness characterized by fever, weakness, <a href="../../../n/e/p/Nephrolithiasis.html" title="Nephrolithiasis">urinary stones</a>, and substantial <a href="../../../h/e/p/Hepatosplenomegaly.html" title="Hepatosplenomegaly">enlargement of the liver and spleen</a>. Velpeau noted that the blood of this patient had a consistency "like gruel", and speculated that the appearance of the blood was due to white corpuscles.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[2]</a></sup> In <a href="../../../1/8/4/1845.html" title="1845">1845</a>, a series of patients who died with enlarged spleens and changes in the "colors and consistencies of their blood" was reported by the <a href="../../../e/d/i/Edinburgh.html" title="Edinburgh">Edinburgh</a>-based <a href="../../../p/a/t/Pathologist.html" title="Pathologist">pathologist</a> J.H. Bennett; he used the term "leucocythemia" to describe this pathological condition.<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[3]</a></sup></p>
<p>The term "leukemia" was coined by <a href="../../../r/u/d/Rudolf_Virchow_fd6b.html" title="Rudolf Virchow">Rudolf Virchow</a>, the renowned German <a href="../../../p/a/t/Pathologist.html" title="Pathologist">pathologist</a>, in <a href="../../../1/8/5/1856.html" title="1856">1856</a>. As a pioneer in the use of the <a href="../../../l/i/g/Light_microscope.html" title="Light microscope">light microscope</a> in pathology, Virchow was the first to describe the abnormal excess of white blood cells in patients with the clinical syndrome described by Velpeau and Bennett. As Virchow was uncertain of the <a href="../../../e/t/i/Etiology.html" title="Etiology">cause</a> of the white blood cell excess, he used the purely descriptive term "leukemia" (Greek: "white blood") to refer to the condition.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[4]</a></sup></p>
<p>Further advances in the understanding of acute myeloid leukemia occurred rapidly with the development of new technology. In <a href="../../../1/8/7/1877.html" title="1877">1877</a>, <a href="../../../p/a/u/Paul_Ehrlich_a52c.html" title="Paul Ehrlich">Paul Ehrlich</a> developed a technique of <a href="../../../s/t/a/Staining_%28biology%29.html" title="Staining (biology)">staining</a> blood films which allowed him to describe in detail normal and abnormal white blood cells. <a href="../../../w/i/l/Wilhelm_Ebstein_319f.html" title="Wilhelm Ebstein">Wilhelm Ebstein</a> introduced the term <i>"acute leukemia"</i> in <a href="../../../1/8/8/1889.html" title="1889">1889</a> to differentiate rapidly progressive and fatal leukemias from the more indolent <a href="../../../c/h/r/Chronic_leukemia.html" title="Chronic leukemia">chronic leukemias</a>.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[5]</a></sup> The term "myeloid" was coined by Neumann in 1869, as he was the first to recognize that white blood cells were made in the bone marrow (<a href="../../../a/n/c/Ancient_Greek_c878.html" title="Ancient Greek">Greek</a>: µυєλός, <i>myelos</i> = (bone) marrow) as opposed to the <a href="../../../s/p/l/Spleen.html" title="Spleen">spleen</a>. The technique of <a href="../../../b/o/n/Bone_marrow_examination.html" title="Bone marrow examination">bone marrow examination</a> to diagnose leukemia was first described in <a href="../../../1/8/7/1879.html" title="1879">1879</a> by Mosler.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[6]</a></sup> Finally, in <a href="../../../1/9/0/1900.html" title="1900">1900</a> the <a href="../../../m/y/e/Myeloblast.html" title="Myeloblast">myeloblast</a>, which is the malignant cell in AML, was characterized by Naegeli, who divided the leukemias into <i>myeloid</i> and <i>lymphocytic</i>.<sup id="_ref-5" class="reference"><a href="#_note-5" title="">[7]</a></sup></p>
<p><a name="Symptoms" id="Symptoms"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Symptoms">edit</a>]</span> <span class="mw-headline">Symptoms</span></h2>
<p>Most signs and symptoms of AML are due to an increased number of malignant white blood cells displacing or otherwise interfering with <a href="../../../h/a/e/Haematopoiesis.html" title="Haematopoiesis">production of normal blood cells</a> in the <a href="../../../b/o/n/Bone_marrow.html" title="Bone marrow">bone marrow</a>. A lack of normal white blood cell production makes the patient susceptible to infections (while the leukemic cells themselves are derived from white blood cell precursors, they have no infection-fighting capacity).<sup id="_ref-symptoms_0" class="reference"><a href="#_note-symptoms" title="">[8]</a></sup> A lack of red blood cells (<a href="../../../a/n/e/Anemia.html" title="Anemia">anemia</a>) can cause fatigue, paleness, and shortness of breath. A lack of <a href="../../../p/l/a/Platelet.html" title="Platelet">platelets</a> can lead to easy bruising or bleeding with minor trauma.</p>
<p>The early signs of AML are often non-specific, and may be similar to those of <a href="../../../i/n/f/Influenza.html" title="Influenza">influenza</a> or other common illnesses. Some generalized symptoms include <a href="../../../f/e/v/Fever.html" title="Fever">fever</a>, <a href="../../../f/a/t/Fatigue_%28physical%29.html" title="Fatigue (physical)">fatigue</a>, <a href="../../../w/e/i/Weight_loss.html" title="Weight loss">weight loss</a> or <a href="../../../l/o/s/Loss_of_appetite.html" title="Loss of appetite">loss of appetite</a>, <a href="../../../d/y/s/Dyspnea.html" title="Dyspnea">shortness of breath</a> with exertion, <a href="../../../a/n/e/Anemia.html" title="Anemia">anemia</a>, easy <a href="../../../b/r/u/Bruising.html" title="Bruising">bruising</a> or <a href="../../../b/l/e/Bleeding.html" title="Bleeding">bleeding</a>, <a href="../../../p/e/t/Petechia.html" title="Petechia">petechiae</a> (flat, pin-head sized spots under the skin caused by bleeding), <a href="../../../b/o/n/Bone_pain.html" title="Bone pain">bone pain</a> and <a href="../../../j/o/i/Joint_pain.html" title="Joint pain">joint pain</a> and persistent or frequent <a href="../../../i/n/f/Infections.html" title="Infections">infections</a>.<sup id="_ref-symptoms_1" class="reference"><a href="#_note-symptoms" title="">[8]</a></sup></p>
<p><a href="../../../s/p/l/Splenomegaly.html" title="Splenomegaly">Enlargement of the spleen</a> may occur in AML, but it is typically mild and <a href="../../../a/s/y/Asymptomatic.html" title="Asymptomatic">asymptomatic</a>. <a href="../../../l/y/m/Lymphadenopathy.html" title="Lymphadenopathy">Lymph node swelling</a> is rare in AML, in contrast to <a href="../../../a/c/u/Acute_lymphoblastic_leukemia.html" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a>. The skin is involved about 10% of the time in the form of <a href="../../../c/h/l/Chloroma.html" title="Chloroma">leukemia cutis</a>. Rarely, <a href="../../../s/w/e/Sweet_syndrome.html" title="Sweet syndrome">Sweet's syndrome</a>, a <a href="../../../p/a/r/Paraneoplastic_syndrome.html" title="Paraneoplastic syndrome">paraneoplastic</a> inflammation of the skin, can occur with AML.<sup id="_ref-symptoms_2" class="reference"><a href="#_note-symptoms" title="">[8]</a></sup></p>
<p>Some patients with AML may experience swelling of the gums due to infiltration of leukemic cells into the gum tissue. Rarely, the first sign of leukemia may be the development of a solid leukemic mass or tumor outside of the <a href="../../../b/o/n/Bone_marrow.html" title="Bone marrow">bone marrow</a>, called a <a href="../../../c/h/l/Chloroma.html" title="Chloroma">chloroma</a>. Occasionally, a person may show <a href="../../../a/s/y/Asymptomatic.html" title="Asymptomatic">no symptoms</a>, and the leukemia may be discovered incidentally during a routine blood test.<sup id="_ref-6" class="reference"><a href="#_note-6" title="">[9]</a></sup></p>
<p><a name="Causes" id="Causes"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Causes">edit</a>]</span> <span class="mw-headline">Causes</span></h2>
<p>A number of risk factors for developing AML have been identified, including:</p>
<ul>
<li>"Pre-leukemic" blood disorders such as <a href="../../../m/y/e/Myelodysplastic_syndrome.html" title="Myelodysplastic syndrome">myelodysplastic</a> or <a href="../../../m/y/e/Myeloproliferative_syndrome.html" title="Myeloproliferative syndrome">myeloproliferative</a> syndromes can evolve into AML; the exact risk depends on the type of MDS/MPS.<sup id="_ref-7" class="reference"><a href="#_note-7" title="">[10]</a></sup></li>
<li>Exposure to <a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">anti-cancer chemotherapy</a>, in particular <a href="../../../a/l/k/Alkylating_agent.html" title="Alkylating agent">alkylating agents</a>, can increase the risk for the subsequent development of AML. The risk is highest about 3-5 years after chemotherapy.<sup id="_ref-8" class="reference"><a href="#_note-8" title="">[11]</a></sup> Other chemotherapy agents, specifically <a href="../../../p/o/d/Podophyllotoxin.html" title="Podophyllotoxin">epipodophyllotoxins</a> and <a href="../../../a/n/t/Anthracycline.html" title="Anthracycline">anthracyclines</a>, have also been associated with treatment-related leukemia. These treatment-related leukemias are often associated with specific chromosomal abnormalities in the leukemic cells.<sup id="_ref-9" class="reference"><a href="#_note-9" title="">[12]</a></sup></li>
<li><a href="../../../i/o/n/Ionizing_radiation.html" title="Ionizing radiation">Ionizing radiation</a> exposure can increase the risk of AML. Survivors of the <a href="../../../a/t/o/Atomic_bombings_of_Hiroshima_and_Nagasaki_2ade.html" title="Atomic bombings of Hiroshima and Nagasaki">atomic bombings of Hiroshima and Nagasaki</a> had an increased rate of AML,<sup id="_ref-10" class="reference"><a href="#_note-10" title="">[13]</a></sup> as did <a href="../../../r/a/d/Radiologist.html" title="Radiologist">radiologists</a> exposed to high levels of <a href="../../../x/-/r/X-ray.html" title="X-ray">X-rays</a> prior to the adoption of modern radiation safety practices.<sup id="_ref-11" class="reference"><a href="#_note-11" title="">[14]</a></sup></li>
<li>Occupational chemical exposure to <a href="../../../b/e/n/Benzene.html" title="Benzene">benzene</a> and other <a href="../../../o/r/g/Organic_solvent.html" title="Organic solvent">aromatic organic solvents</a> is controversial as a cause of AML. Benzene and many of its derivatives are known to be <a href="../../../c/a/r/Carcinogenic.html" title="Carcinogenic">carcinogenic</a> <i>in vitro</i>. While some studies have suggested a link between occupational exposure to benzene and increased risk of AML,<sup id="_ref-12" class="reference"><a href="#_note-12" title="">[15]</a></sup> others have suggested that the attributable risk, if any, is slight.<sup id="_ref-13" class="reference"><a href="#_note-13" title="">[16]</a></sup></li>
<li>Several <a href="../../../c/o/n/Congenital.html" title="Congenital">congenital</a> conditions may increase the risk of leukemia; the most common is probably <a href="../../../d/o/w/Down_syndrome.html" title="Down syndrome">Down syndrome</a>, which is associated with a 10- to 18-fold increase in the risk of AML.<sup id="_ref-14" class="reference"><a href="#_note-14" title="">[17]</a></sup></li>
</ul>
<p><a name="Epidemiology" id="Epidemiology"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Epidemiology">edit</a>]</span> <span class="mw-headline">Epidemiology</span></h2>
<p>Acute myeloid leukemia is a relatively rare cancer. There are approximately 10,500 new cases each year in the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a>, and the <a href="../../../i/n/c/Incidence_%28epidemiology%29.html" title="Incidence (epidemiology)">incidence</a> rate has remained stable from 1995 through 2005. AML accounts for 1.2% of all cancer deaths in the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a>.<sup id="_ref-cancerstats_1" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup></p>
<p>The incidence of AML increases with age; the median age at diagnosis is 63 years. AML accounts for about 90% of all acute leukemias in adults, but is rare in children.<sup id="_ref-cancerstats_2" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup> The rate of <i>therapy-related AML</i> (that is, AML caused by previous chemotherapy) is rising; therapy-related disease currently accounts for about 10-20% of all cases of AML.<sup id="_ref-15" class="reference"><a href="#_note-15" title="">[18]</a></sup> AML is slightly more common in men, with a male-to-female ratio of 1.3:1.<sup id="_ref-16" class="reference"><a href="#_note-16" title="">[19]</a></sup></p>
<p>There is some geographic variation in the incidence of AML. In adults, the highest rates are seen in <a href="../../../n/o/r/North_America_e7c4.html" title="North America">North America</a>, <a href="../../../e/u/r/Europe.html" title="Europe">Europe</a>, and <a href="../../../o/c/e/Oceania.html" title="Oceania">Oceania</a>, while adult AML is rarer in <a href="../../../a/s/i/Asia.html" title="Asia">Asia</a> and <a href="../../../l/a/t/Latin_America_2c96.html" title="Latin America">Latin America</a>.<sup id="_ref-17" class="reference"><a href="#_note-17" title="">[20]</a></sup><sup id="_ref-18" class="reference"><a href="#_note-18" title="">[21]</a></sup> In contrast, childhood AML is less common in North America and <a href="../../../i/n/d/India.html" title="India">India</a> than in other parts of Asia.<sup id="_ref-19" class="reference"><a href="#_note-19" title="">[22]</a></sup> These differences may be due to population genetics, environmental factors, or a combination of the two.</p>
<p>A hereditary risk for AML appears to exist. There are numerous reports of multiple cases of AML developing in a family at a rate higher than predicted by chance alone.<sup id="_ref-20" class="reference"><a href="#_note-20" title="">[23]</a></sup><sup id="_ref-21" class="reference"><a href="#_note-21" title="">[24]</a></sup><sup id="_ref-22" class="reference"><a href="#_note-22" title="">[25]</a></sup><sup id="_ref-23" class="reference"><a href="#_note-23" title="">[26]</a></sup> The risk of developing AML is increased threefold in <a href="../../../f/i/r/First_degree_relative.html" title="First degree relative">first-degree relatives</a> of patients with AML.<sup id="_ref-24" class="reference"><a href="#_note-24" title="">[27]</a></sup></p>
<p><a name="Pathophysiology" id="Pathophysiology"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Pathophysiology">edit</a>]</span> <span class="mw-headline">Pathophysiology</span></h2>
<p>The malignant cell in AML is the <a href="../../../m/y/e/Myeloblast.html" title="Myeloblast">myeloblast</a>. In normal <a href="../../../h/a/e/Haematopoiesis.html" title="Haematopoiesis">hematopoiesis</a>, the myeloblast is an immature precursor of <a href="../../../m/y/e/Myeloid.html" title="Myeloid">myeloid</a> white blood cells; a normal myeloblast will gradually mature into a mature white blood cell. However, in AML, a single myeloblast accumulates genetic changes which "freeze" the cell in its immature state and prevent <a href="../../../c/e/l/Cellular_differentiation.html" title="Cellular differentiation">differentiation</a>.<sup id="_ref-25" class="reference"><a href="#_note-25" title="">[28]</a></sup> Such a mutation alone does not cause leukemia; however, when such a "differentiation arrest" is <a href="../../../k/n/u/Knudson_hypothesis.html" title="Knudson hypothesis">combined with other mutations</a> which disrupt genes controlling <a href="../../../c/e/l/Cell_growth.html" title="Cell growth">proliferation</a>, the result is the uncontrolled growth of an immature clone of cells, leading to the clinical entity of AML.<sup id="_ref-26" class="reference"><a href="#_note-26" title="">[29]</a></sup></p>
<p>Much of the diversity and heterogeneity of AML stems from the fact that leukemic transformation can occur at a number of different steps along the differentiation pathway.<sup id="_ref-27" class="reference"><a href="#_note-27" title="">[30]</a></sup> Modern classification schemes for AML recognize that the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.</p>
<p>Specific <a href="../../../c/y/t/Cytogenetics.html" title="Cytogenetics">cytogenetic</a> abnormalities can be found in many patients with AML; the types of chromosomal abnormalities often have <a href="../../../p/r/o/Prognosis.html" title="Prognosis">prognostic</a> significance.<sup id="_ref-28" class="reference"><a href="#_note-28" title="">[31]</a></sup> The chromosomal <a href="../../../t/r/a/Translocations.html" title="Translocations">translocations</a> encode abnormal fusion <a href="../../../p/r/o/Proteins.html" title="Proteins">proteins</a>, usually <a href="../../../t/r/a/Transcription_factors.html" title="Transcription factors">transcription factors</a> whose altered properties may cause the "differentiation arrest."<sup id="_ref-29" class="reference"><a href="#_note-29" title="">[32]</a></sup> For example, in <a href="../../../a/c/u/Acute_promyelocytic_leukemia.html" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a>, the t(15;17) translocation produces a PML-RARα <a href="../../../f/u/s/Fusion_protein.html" title="Fusion protein">fusion protein</a> which binds to the <a href="../../../r/e/t/Retinoic_acid.html" title="Retinoic acid">retinoic acid</a> receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.<sup id="_ref-30" class="reference"><a href="#_note-30" title="">[33]</a></sup></p>
<p>The clinical signs and symptoms of AML result from the fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the development of normal blood cells in the bone marrow.<sup id="_ref-31" class="reference"><a href="#_note-31" title="">[34]</a></sup> This leads to <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">neutropenia</a>, <a href="../../../a/n/e/Anemia.html" title="Anemia">anemia</a>, and <a href="../../../t/h/r/Thrombocytopenia.html" title="Thrombocytopenia">thrombocytopenia</a>. The symptoms of AML are in turn often due to the low numbers of these normal blood elements. In rare cases, patients can develop a <i><a href="../../../c/h/l/Chloroma.html" title="Chloroma">chloroma</a></i>, or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.<sup id="_ref-symptoms_3" class="reference"><a href="#_note-symptoms" title="">[8]</a></sup></p>
<p><a name="Diagnosis" id="Diagnosis"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Diagnosis">edit</a>]</span> <span class="mw-headline">Diagnosis</span></h2>
<p>The first clue to a diagnosis of AML is typically an abnormal result on a <a href="../../../c/o/m/Complete_blood_count.html" title="Complete blood count">complete blood count</a>. While an excess of abnormal white blood cells (<a href="../../../l/e/u/Leukocytosis.html" title="Leukocytosis">leukocytosis</a>) is a common finding,and leukemic blasts are sometimes seen, AML can also present with isolated decreases in <a href="../../../p/l/a/Platelet.html" title="Platelet">platelets</a>, <a href="../../../r/e/d/Red_blood_cell.html" title="Red blood cell">red blood cells</a>, or even with a <i>low</i> white blood cell count (<a href="../../../l/e/u/Leukopenia.html" title="Leukopenia">leukopenia</a>).<sup id="_ref-32" class="reference"><a href="#_note-32" title="">[35]</a></sup> While a presumptive diagnosis of AML can be made via examination of the peripheral blood smear when there are circulating leukemic blasts, a definitive diagnosis usually requires an adequate bone marrow aspiration and biopsy</p>
<p>A <a href="../../../b/o/n/Bone_marrow_examination.html" title="Bone marrow examination">bone marrow examination</a> is often performed to identify the type of abnormal blood cells; however, if there are many leukemic cells circulating in the peripheral blood, a bone marrow <a href="../../../b/i/o/Biopsy.html" title="Biopsy">biopsy</a> may not be necessary. Marrow or blood is examined via <a href="../../../l/i/g/Light_microscopy.html" title="Light microscopy">light microscopy</a> as well as <a href="../../../f/l/o/Flow_cytometry.html" title="Flow cytometry">flow cytometry</a> to diagnose the presence of leukemia, to differentiate AML from other types of leukemia (e.g. <a href="../../../a/c/u/Acute_lymphoblastic_leukemia.html" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a>), and to classify the subtype of disease (see below). A sample of marrow or blood is typically also tested for <a href="../../../c/h/r/Chromosomal_translocation.html" title="Chromosomal translocation">chromosomal translocations</a> by routine <a href="../../../c/y/t/Cytogenetics.html" title="Cytogenetics">cytogenetics</a> or <a href="../../../f/l/u/Fluorescent_in_situ_hybridization.html" title="Fluorescent in situ hybridization">fluorescent in situ hybridization</a>.</p>
<p>The diagnosis and classification of AML can be challenging, and should be performed by a qualified <a href="../../../h/e/m/Hematopathologist.html" title="Hematopathologist">hematopathologist</a> or <a href="../../../h/e/m/Hematologist.html" title="Hematologist">hematologist</a>. In straightforward cases, the presence of certain morphologic features (such as <a href="../../../a/u/e/Auer_rods.html" title="Auer rods">Auer rods</a>) or specific flow cytometry results can distinguish AML from other leukemias; however, in the absence of such features, diagnosis may be more difficult.<sup id="_ref-33" class="reference"><a href="#_note-33" title="">[36]</a></sup></p>
<p>According to the widely used <a href="../../../w/h/o/WHO_9ed1.html" title="WHO">WHO</a> criteria, the diagnosis of AML is established by demonstrating involvement of more than 20% of the blood and/or bone marrow by leukemic <a href="../../../m/y/e/Myeloblast.html" title="Myeloblast">myeloblasts</a>.<sup id="_ref-34" class="reference"><a href="#_note-34" title="">[37]</a></sup> AML must be carefully differentiated from "pre-leukemic" conditions such as <a href="../../../m/y/e/Myelodysplastic_syndrome.html" title="Myelodysplastic syndrome">myelodysplastic</a> or <a href="../../../m/y/e/Myeloproliferative_syndrome.html" title="Myeloproliferative syndrome">myeloproliferative</a> syndromes, which are treated differently.</p>
<p>Because <a href="../../../a/c/u/Acute_promyelocytic_leukemia.html" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a> (APL) has the highest curability and requires a unique form of treatment, it is important to quickly establish or exclude the diagnosis of this subtype of leukemia. <a href="../../../f/l/u/Fluorescent_in_situ_hybridization.html" title="Fluorescent in situ hybridization">Fluorescent in situ hybridization</a> performed on blood or bone marrow is often used for this purpose, as it readily identifies the <a href="../../../c/h/r/Chromosomal_translocation.html" title="Chromosomal translocation">chromosomal translocation</a> (t[15;17]) that characterizes APL.<sup id="_ref-35" class="reference"><a href="#_note-35" title="">[38]</a></sup></p>
<p><a name="Classification" id="Classification"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Classification">edit</a>]</span> <span class="mw-headline">Classification</span></h2>
<p>The two most commonly used classification schemata for AML, <a href="../../../a/s/_/As_of_2006.html" title="As of 2006">as of 2006</a>, are the older French-American-British (FAB) system and the newer <a href="../../../w/o/r/World_Health_Organization_57ba.html" title="World Health Organization">World Health Organization</a> (WHO) system.</p>
<p><a name="French-American-British_classification" id="French-American-British_classification"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: French-American-British classification">edit</a>]</span> <span class="mw-headline">French-American-British classification</span></h3>
<p>The French-American-British (FAB) classification system divided AML into 8 subtypes, M0 through to M7, based on the type of cell from which the leukemia developed and its degree of maturity. This is done by examining the appearance of the malignant cells under <a href="../../../l/i/g/Light_microscopy.html" title="Light microscopy">light microscopy</a> and/or by using <a href="../../../c/y/t/Cytogenetics.html" title="Cytogenetics">cytogenetics</a> to characterize any underlying chromosomal abnormalities. The subtypes have varying prognoses and responses to therapy. Although the WHO classification (see below) may be more useful, the FAB system is still widely used as of mid-2006.</p>
<p>The eight FAB subtypes are:<sup id="_ref-36" class="reference"><a href="#_note-36" title="">[39]</a></sup></p>
<ul>
<li>M0 (<a href="../../../u/n/d/Undifferentiated.html" title="Undifferentiated">undifferentiated</a> AML)</li>
<li>M1 (myeloblastic, without maturation)</li>
<li><a href="../../../m/2/_/M2_AML_3bdc.html" title="M2 AML">M2</a> (myeloblastic, with maturation)</li>
<li>M3 (promyelocytic), or <a href="../../../a/c/u/Acute_promyelocytic_leukemia.html" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a> (APL)</li>
<li>M4 (myelomonocytic)</li>
<li>M4eo (myelomonocytic together with bone marrow <a href="../../../e/o/s/Eosinophil.html" title="Eosinophil">eosinophilia</a>)</li>
<li>M5 <a href="../../../m/o/n/Monoblastic_leukemia.html" title="Monoblastic leukemia">monoblastic leukemia</a> (M5a) or <a href="../../../m/o/n/Monocytic_leukemia.html" title="Monocytic leukemia">monocytic leukemia</a> (M5b)</li>
<li>M6 (erythrocytic), or <a href="../../../e/r/y/Erythroleukemia.html" title="Erythroleukemia">erythroleukemia</a></li>
<li>M7 (megakaryoblastic)</li>
</ul>
<p><a name="World_Health_Organization_classification" id="World_Health_Organization_classification"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: World Health Organization classification">edit</a>]</span> <span class="mw-headline">World Health Organization classification</span></h3>
<p>The <a href="../../../w/o/r/World_Health_Organization_57ba.html" title="World Health Organization">World Health Organization</a> (WHO) classification of acute myeloid leukemia attempts to be more clinically useful and to produce more meaningful prognostic information than the FAB criteria. Each of the WHO categories contains numerous descriptive sub-categories of interest to the <a href="../../../h/e/m/Hematopathologist.html" title="Hematopathologist">hematopathologist</a> and <a href="../../../o/n/c/Oncologist.html" title="Oncologist">oncologist</a>; however, most of the clinically significant information in the WHO schema is communicated via categorization into one of the five subtypes listed below.</p>
<p>The WHO subtypes of AML are:<sup id="_ref-37" class="reference"><a href="#_note-37" title="">[40]</a></sup></p>
<ul>
<li><b>AML with characteristic genetic abnormalities</b>, which includes AML with translocations between chromosome 8 and 21 [t(8;21)], inversions in chromosome 16 [inv(16)], or translocations between chromosome 15 and 17 [t(15;17)]. Patients with AML in this category generally have a high rate of remission and a better prognosis compared to other types of AML.</li>
<li><b>AML with multilineage dysplasia</b>. This category includes patients who have had a prior <a href="../../../m/y/e/Myelodysplastic_syndrome.html" title="Myelodysplastic syndrome">myelodysplastic syndrome</a> (MDS) or <a href="../../../m/y/e/Myeloproliferative_disease.html" title="Myeloproliferative disease">myeloproliferative disease</a> (MPD) that transforms into AML. This category of AML occurs most often in elderly patients and often has a worse prognosis.</li>
<li><b>AML and MDS, therapy-related</b>. This category includes patients who have had prior chemotherapy and/or radiation and subsequently develop AML or MDS. These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis.</li>
<li><b>AML not otherwise categorized</b>. Includes subtypes of AML that do not fall into the above categories.</li>
<li><b>Acute leukemias of ambiguous lineage</b>. Acute leukemias of ambiguous lineage (also known as mixed phenotype or biphenotypic acute leukemia) occur when the leukemic cells can not be classified as either myeloid or lymphoid cells, or where both types of cells are present.</li>
</ul>
<p><a name="Prognosis" id="Prognosis"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Prognosis">edit</a>]</span> <span class="mw-headline">Prognosis</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:127px;"><a href="../../../9/3B/1/Image%7E9%3B11.rhyax.jpg.html" class="internal" title="Chromosomal translocation (9;11), associated with AML"><img src="../../../upload/shared/thumb/c/c7/9%3B11.rhyax.jpg/125px-9%3B11.rhyax.jpg" alt="Chromosomal translocation (9;11), associated with AML" width="125" height="156" longdesc="../../../9/3B/1/Image%7E9%3B11.rhyax.jpg.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../9/3B/1/Image%7E9%3B11.rhyax.jpg.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Chromosomal translocation (9;11), associated with AML</div>
</div>
</div>
<p>Acute myeloid leukemia is a curable disease; the chance of cure for a specific patient depends on a number of prognostic factors.<sup id="_ref-prog_0" class="reference"><a href="#_note-prog" title="">[41]</a></sup></p>
<p><a name="Cytogenetics_and_prognosis_in_AML" id="Cytogenetics_and_prognosis_in_AML"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Cytogenetics and prognosis in AML">edit</a>]</span> <span class="mw-headline">Cytogenetics and prognosis in AML</span></h3>
<p>The single most important prognostic factor in AML is <a href="../../../c/y/t/Cytogenetics.html" title="Cytogenetics">cytogenetics</a>, or the chromosomal structure of the leukemic cell. Certain cytogenetic abnormalities are associated with very good outcomes (for example, the (15;17) translocation in <a href="../../../a/c/u/Acute_promyelocytic_leukemia.html" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a>). About half of AML patients have "normal" cytogenetics; they fall into an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor prognosis and a high risk of relapse after treatment.<sup id="_ref-38" class="reference"><a href="#_note-38" title="">[42]</a></sup><sup id="_ref-39" class="reference"><a href="#_note-39" title="">[43]</a></sup><sup id="_ref-40" class="reference"><a href="#_note-40" title="">[44]</a></sup></p>
<p>The first publication to address cytogenetics and prognosis was the MRC trial of 1998:<sup id="_ref-41" class="reference"><a href="#_note-41" title="">[45]</a></sup></p>
<table class="wikitable">
<tr>
<th>Risk Category</th>
<th>Abnormality</th>
<th>5-year survival</th>
<th>Relapse rate</th>
</tr>
<tr>
<td>Favorable</td>
<td>t(8;21), t(15;17), inv(16)</td>
<td>70%</td>
<td>33%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Normal, +8, +21, +22, del(7q), del(9q), Abnormal 11q23, all other structural or numerical changes</td>
<td>48%</td>
<td>50%</td>
</tr>
<tr>
<td>Adverse</td>
<td>-5, -7, del(5q), Abnormal 3q, Complex cytogenetics</td>
<td>15%</td>
<td>78%</td>
</tr>
</table>
<p>Later, the <a href="../../../s/o/u/Southwest_Oncology_Group_6296.html" title="Southwest Oncology Group">Southwest Oncology Group</a> and <a href="../../../e/a/s/Eastern_Cooperative_Oncology_Group_36a9.html" title="Eastern Cooperative Oncology Group">Eastern Cooperative Oncology Group</a>,<sup id="_ref-42" class="reference"><a href="#_note-42" title="">[46]</a></sup> and later still, <a href="../../../c/a/n/Cancer_and_Leukemia_Group_B_54ab.html" title="Cancer and Leukemia Group B">Cancer and Leukemia Group B</a> published other, mostly overlapping lists of cytogenetics prognostication in leukemia<sup id="_ref-43" class="reference"><a href="#_note-43" title="">[47]</a></sup></p>
<p><a name="Antecedent_MDS_and_prognosis" id="Antecedent_MDS_and_prognosis"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Antecedent MDS and prognosis">edit</a>]</span> <span class="mw-headline">Antecedent MDS and prognosis</span></h3>
<p>AML which arises from a pre-existing <a href="../../../m/y/e/Myelodysplastic_syndrome.html" title="Myelodysplastic syndrome">myelodysplastic syndrome</a> or <a href="../../../m/y/e/Myeloproliferative_disease.html" title="Myeloproliferative disease">myeloproliferative disease</a> (so-called <i>secondary AML</i>) has a worse prognosis, as does <i>treatment-related AML</i> arising after chemotherapy for another previous malignancy. Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities.<sup id="_ref-44" class="reference"><a href="#_note-44" title="">[48]</a></sup><sup id="_ref-45" class="reference"><a href="#_note-45" title="">[49]</a></sup><sup id="_ref-46" class="reference"><a href="#_note-46" title="">[50]</a></sup></p>
<p><a name="Other_prognostic_markers" id="Other_prognostic_markers"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Other prognostic markers">edit</a>]</span> <span class="mw-headline">Other prognostic markers</span></h3>
<p>In some studies, age &gt;60 years and elevated <a href="../../../l/a/c/Lactate_dehydrogenase.html" title="Lactate dehydrogenase">lactate dehydrogenase</a> level were also associated with poorer outcomes.<sup id="_ref-47" class="reference"><a href="#_note-47" title="">[51]</a></sup> As with most forms of cancer, performance status (i.e. the general physical condition and activity level of the patient) plays a major role in prognosis as well.</p>
<p><a href="../../../f/l/t/FLT3_7b91.html" title="FLT3">FLT3</a> internal tandem duplications (ITDs) have been shown to confer a poorer prognosis in AML.<sup id="_ref-48" class="reference"><a href="#_note-48" title="">[52]</a></sup> Treating these patients with more aggressive therapy, such as stem-cell transplantation in first remission, has not been shown to enhance long-term survival, so this prognostic feature is of uncertain clinical significance at this point.<sup id="_ref-49" class="reference"><a href="#_note-49" title="">[53]</a></sup></p>
<p>Researchers are investigating the clinical significance of <a href="../../../c/-/k/C-KIT_8dd1.html" title="C-KIT">c-KIT</a> mutations<sup id="_ref-50" class="reference"><a href="#_note-50" title="">[54]</a></sup> in AML. These are prevalent, and clinically relevant because of the availability of tyrosine kinase inhibitors, such as <a href="../../../s/u/n/Sunitinib.html" title="Sunitinib">sunitinib</a> and <a href="../../../i/m/a/Imatinib.html" title="Imatinib">imatinib</a> that can block the activity of <a href="../../../c/-/k/C-KIT_8dd1.html" title="C-KIT">c-KIT</a> pharmacologically.</p>
<p>Other genes being investigated as prognostic factors or therapeutic targets include CEBPA, BAALC, <a href="../../../e/r/g/ERG_a32a.html" title="ERG">ERG</a>, and NPM1.</p>
<p><a name="Overall_expectation_of_cure" id="Overall_expectation_of_cure"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Overall expectation of cure">edit</a>]</span> <span class="mw-headline">Overall expectation of cure</span></h3>
<p>Cure rates in clinical trials have ranged from 20-45%;<sup id="_ref-51" class="reference"><a href="#_note-51" title="">[55]</a></sup><sup id="_ref-52" class="reference"><a href="#_note-52" title="">[56]</a></sup> however, it should be noted that clinical trials often include only younger patients and those able to tolerate aggressive therapies. The overall cure rate for all patients with AML (including the elderly and those unable to tolerate aggressive therapy) is likely lower. Cure rates for promyelocytic leukemia can be as high as 98%.<sup id="_ref-53" class="reference"><a href="#_note-53" title="">[57]</a></sup></p>
<p><a name="Treatment" id="Treatment"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h2>
<p>Treatment of AML consists primarily of <a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">chemotherapy</a>, and is divided into two phases: <i>induction</i> and <i>postremission</i> (or <i>consolidation</i>) therapy. The goal of <i>induction</i> therapy is to achieve a complete remission by reducing the amount of leukemic cells to an undetectable level; the goal of <i>consolidation</i> therapy is to eliminate any residual undetectable disease and achieve a cure.</p>
<p><a name="Induction" id="Induction"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Induction">edit</a>]</span> <span class="mw-headline">Induction</span></h3>
<p><a href="../../../a/s/_/As_of_2006.html" title="As of 2006">As of 2006</a>, all FAB subtypes except M3 are usually given induction chemotherapy with <a href="../../../c/y/t/Cytarabine.html" title="Cytarabine">cytarabine</a> (ara-C) and an <a href="../../../a/n/t/Anthracycline.html" title="Anthracycline">anthracycline</a> (such as <a href="../../../d/a/u/Daunorubicin.html" title="Daunorubicin">daunorubicin</a> or <a href="../../../i/d/a/Idarubicin.html" title="Idarubicin">idarubicin</a>).<sup id="_ref-treatment_0" class="reference"><a href="#_note-treatment" title="">[58]</a></sup> Other alternatives, including high-dose ara-C alone, may also be used.<sup id="_ref-54" class="reference"><a href="#_note-54" title="">[59]</a></sup><sup id="_ref-55" class="reference"><a href="#_note-55" title="">[60]</a></sup> Because of the toxic effects of therapy, including <a href="../../../m/y/e/Myelosuppression.html" title="Myelosuppression">myelosuppression</a> and an increased risk of infection, induction chemotherapy may not offered to the very elderly. Induction chemotherapy usually requires a hospitalization of about 1 month to receive the chemotherapy and recover from its side effects.</p>
<p>Induction chemotherapy is known as "7 and 3" because the <a href="../../../c/y/t/Cytarabine.html" title="Cytarabine">cytarabine</a> is given as a continuous IV infusion for seven consecutive days, while the <a href="../../../a/n/t/Anthracycline.html" title="Anthracycline">anthracycline</a> is given for three consecutive days as an IV push. Up to 70% of patients will achieve a remission with this protocol.<sup id="_ref-56" class="reference"><a href="#_note-56" title="">[61]</a></sup></p>
<p>The M3 subtype of AML, also known as <a href="../../../a/c/u/Acute_promyelocytic_leukemia.html" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a>, is almost universally treated with the drug <a href="../../../a/t/r/ATRA_2e7d.html" title="ATRA">ATRA</a> (all-<i>trans</i>-retinoic acid) in addition to induction chemotherapy.<sup id="_ref-57" class="reference"><a href="#_note-57" title="">[62]</a></sup><sup id="_ref-58" class="reference"><a href="#_note-58" title="">[63]</a></sup><sup id="_ref-59" class="reference"><a href="#_note-59" title="">[64]</a></sup> Care must be taken to prevent disseminated intravascular coagulation (<a href="../../../d/i/c/DIC_df0e.html" title="DIC">DIC</a>), complicating the treatment of <a href="../../../a/p/l/APL_cd54.html" title="APL">APL</a> when the promyelocytes release the contents of their granules into the peripheral circulation. <a href="../../../a/p/l/APL_cd54.html" title="APL">APL</a> is eminently curable with well-documented treatment protocols.</p>
<p>The goal of the induction phase is to reach a <i>complete remission</i>. Complete remission does not mean that the disease has been cured; rather, it signifies that no disease can be detected with available diagnostic methods (i.e., &lt;5% leukemic cells remain in the <a href="../../../b/o/n/Bone_marrow.html" title="Bone marrow">bone marrow</a>).<sup id="_ref-treatment_1" class="reference"><a href="#_note-treatment" title="">[58]</a></sup> Complete remission is obtained in about 50%-75% of newly diagnosed adults, although this may vary based on the prognostic factors described above.<sup id="_ref-60" class="reference"><a href="#_note-60" title="">[65]</a></sup></p>
<p>The durability of remission depends on the prognostic features of the original leukemia. In general, all remissions will fail without consolidation (post-remission) chemotherapy, and consolidation has become an important component of treatment.<sup id="_ref-61" class="reference"><a href="#_note-61" title="">[66]</a></sup></p>
<p><a name="Consolidation" id="Consolidation"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Consolidation">edit</a>]</span> <span class="mw-headline">Consolidation</span></h3>
<p>Even after complete remission is achieved, leukemic cells likely remain in numbers too small to be detected with current diagnostic techniques. If no further <i>postremission</i> or consolidation therapy is given, almost all patients will eventually relapse.<sup id="_ref-62" class="reference"><a href="#_note-62" title="">[67]</a></sup> Therefore, more therapy is necessary to eliminate non-detectable disease and prevent relapse — that is, to achieve a cure.</p>
<p>The specific type of postremission therapy is individualized based on a patient's prognostic factors (see above) and general health. For good-prognosis leukemias (i.e. inv(16), t(8;21), and t(15;17)), patients will typically undergo an additional 3-5 courses of intensive chemotherapy, known as <i>consolidation</i> chemotherapy.<sup id="_ref-63" class="reference"><a href="#_note-63" title="">[68]</a></sup><sup id="_ref-nccn_0" class="reference"><a href="#_note-nccn" title="">[69]</a></sup> For patients at high risk of relapse (e.g. those with high-risk cytogenetics, underlying MDS, or therapy-related AML), <a href="../../../b/o/n/Bone_marrow_transplant.html" title="Bone marrow transplant">allogeneic stem cell transplantation</a> is usually recommended if the patient is able to tolerate a transplant and has a suitable donor. The best postremission therapy for intermediate-risk AML (normal cytogenetics or cytogenetic changes not falling into good-risk or high-risk groups) is less clear and depends on the specific situation, including the age and overall health of the patient, the patient's personal values, and whether a suitable stem cell donor is available.<sup id="_ref-nccn_1" class="reference"><a href="#_note-nccn" title="">[69]</a></sup></p>
<p><a name="Relapsed_AML" id="Relapsed_AML"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Relapsed AML">edit</a>]</span> <span class="mw-headline">Relapsed AML</span></h3>
<p>Despite aggressive therapy, however, only 20%-30% of patients enjoy long-term disease-free survival. For patients with relapsed AML, the only proven potentially curative therapy is a <a href="../../../s/t/e/Stem_cell_transplant.html" title="Stem cell transplant">stem cell transplant</a>, if one has not already been performed.<sup id="_ref-relapse_0" class="reference"><a href="#_note-relapse" title="">[70]</a></sup><sup id="_ref-64" class="reference"><a href="#_note-64" title="">[71]</a></sup><sup id="_ref-65" class="reference"><a href="#_note-65" title="">[72]</a></sup> In 2000, <a href="../../../m/y/l/Mylotarg.html" title="Mylotarg">Mylotarg</a> (gemtuzumab zogamicin) was approved in the United States for patients aged more than 60 years with relapsed AML who are not candidates for high-dose chemotherapy.<sup id="_ref-66" class="reference"><a href="#_note-66" title="">[73]</a></sup></p>
<p>Patients with relapsed AML who are not candidates for stem cell transplantion, or who have relapsed after a stem cell transplant, should be strongly considered for enrollment in a <a href="../../../c/l/i/Clinical_trial.html" title="Clinical trial">clinical trial</a>, as conventional treatment options are limited. Agents under investigation include cytotoxic drugs such as <a href="../../../c/l/o/Clofarabine.html" title="Clofarabine">clofarabine</a> as well as <a href="../../../t/a/r/Targeted_therapy.html" title="Targeted therapy">targeted therapies</a> such as <a href="../../../f/a/r/Farnesyltransferase_inhibitor.html" title="Farnesyltransferase inhibitor">farnesyl transferase inhibitors</a>, decitabine, and inhibitors of MDR1 (multidrug-resistance protein). Since treatment options for relapsed AML are so limited, another option which may be offered is <a href="../../../p/a/l/Palliative_care.html" title="Palliative care">palliative care</a>.</p>
<p>For relapsed acute promyelocytic leukemia (APL), <a href="../../../a/r/s/Arsenic_trioxide.html" title="Arsenic trioxide">arsenic trioxide</a> has been tested in trials and approved by the <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">Food and Drug Administration</a>. Like ATRA, arsenic trioxide does not work with other subtypes of AML.<sup id="_ref-67" class="reference"><a href="#_note-67" title="">[74]</a></sup></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../c/h/l/Chloroma.html" title="Chloroma">Chloroma</a></li>
<li><a href="../../../c/h/r/Chronic_myelogenous_leukemia.html" title="Chronic myelogenous leukemia">Chronic myelogenous leukemia</a></li>
<li><a href="../../../a/c/u/Acute_lymphoblastic_leukemia.html" title="Acute lymphoblastic leukemia">Acute lymphoblastic leukemia</a></li>
</ul>
<p><a name="Notes" id="Notes"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: Notes">edit</a>]</span> <span class="mw-headline">Notes</span></h2>
<div class="references-small" style="-moz-column-count: 2; column-count: 2;">
<ol class="references">
<li id="_note-cancerstats">^ <a href="#_ref-cancerstats_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-cancerstats_1" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-cancerstats_2" title=""><sup><i><b>c</b></i></sup></a> Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. <i>CA Cancer J Clin</i> 52:23, 2002. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11814064" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11814064">PMID 11814064</a></li>
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite class="book" style="font-style:normal" id="Reference-Hoffman-2005">Hoffman, Ronald <i>et al.</i> (2005). <i>Hematology: Basic Principles and Practice</i>, 4th. ed., <a href="../../../s/t/_/St_Louis%2C_Missouri_31e6.html" title="St Louis, Missouri">St. Louis, Mo.</a>: <a href="../../../c/h/u/Churchill_Livingstone_597a.html" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>, p. 1071. <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 0-443-06629-9</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Hematology%3A+Basic+Principles+and+Practice&amp;rft.title=Hematology%3A+Basic+Principles+and+Practice&amp;rft.aulast=Hoffman&amp;rft.aufirst=Ronald+%27%27et+al.%27%27&amp;rft.date=2005&amp;rft.edition=4th.+ed.&amp;rft.pub=%5B%5BChurchill+Livingstone%7CElsevier+Churchill+Livingstone%5D%5D&amp;rft.place=%5B%5BSt+Louis%2C+Missouri%7CSt.+Louis%2C+Mo.%5D%5D&amp;rft.pages=p.+1071">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> Bennett JH. Two cases of hypertrophy of the spleen and liver, in which death took place from suppuration of blood. <i>Edinburgh Med Surg J.</i> (1845)64:413.</li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> Virchow R: Die Leukämie. In Virchow R (ed): Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Meidinger, 1856, p 190.</li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> Ebstein W. Ueber die acute Leukämie und Pseudoleukämie. <i>Deutsch Arch Klin Med</i>. (1889)44:343.</li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> Mosler F. Klinische Symptome und Therapie der medullären Leukämie. <i>Berl Klin Wochenschr</i>. (1876)13:702.</li>
<li id="_note-5"><b><a href="#_ref-5" title="">^</a></b> Naegeli O. Über rothes Knochenmark und Myeloblasten. <i>Deutsch Med Wochenschr</i>. (1900) 26:287.</li>
<li id="_note-symptoms">^ <a href="#_ref-symptoms_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-symptoms_1" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-symptoms_2" title=""><sup><i><b>c</b></i></sup></a> <a href="#_ref-symptoms_3" title=""><sup><i><b>d</b></i></sup></a> Hoffman, Ronald et al. (2005), pp. 1074–75.</li>
<li id="_note-6"><b><a href="#_ref-6" title="">^</a></b> <cite class="book" style="font-style:normal" id="Reference-Abeloff-2004">Abeloff, Martin <i>et al.</i> (2004). <i>Clinical Oncology</i>, 3rd. edition, <a href="../../../s/t/_/St_Louis%2C_Missouri_31e6.html" title="St Louis, Missouri">St. Louis, Mo.</a>: <a href="../../../c/h/u/Churchill_Livingstone_597a.html" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>, p. 2834. <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 0-443-06629-9</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Clinical+Oncology&amp;rft.title=Clinical+Oncology&amp;rft.aulast=Abeloff&amp;rft.aufirst=Martin+%27%27et+al.%27%27&amp;rft.date=2004&amp;rft.edition=3rd.+edition&amp;rft.pub=%5B%5BChurchill+Livingstone%7CElsevier+Churchill+Livingstone%5D%5D&amp;rft.place=%5B%5BSt+Louis%2C+Missouri%7CSt.+Louis%2C+Mo.%5D%5D&amp;rft.pages=p.+2834">&#160;</span></li>
<li id="_note-7"><b><a href="#_ref-7" title="">^</a></b> <cite style="font-style:normal">Sanz G, Sanz M, Vallespí T, Cañizo M, Torrabadella M, García S, Irriguible D, San Miguel J (1989). "Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.". <i>Blood</i> <b>74</b> (1): 395-408. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2752119" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2752119">PMID 2752119</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Two+regression+models+and+a+scoring+system+for+predicting+survival+and+planning+treatment+in+myelodysplastic+syndromes%3A+a+multivariate+analysis+of+prognostic+factors+in+370+patients.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=1989&amp;rft.volume=74&amp;rft.issue=1&amp;rft.au=Sanz+G%2C+Sanz+M%2C+Vallesp%C3%AD+T%2C+Ca%C3%B1izo+M%2C+Torrabadella+M%2C+Garc%C3%ADa+S%2C+Irriguible+D%2C+San+Miguel+J&amp;rft.pages=395-408&amp;rft_id=info:pmid/2752119">&#160;</span></li>
<li id="_note-8"><b><a href="#_ref-8" title="">^</a></b> <cite style="font-style:normal">Le Beau M, Albain K, Larson R, Vardiman J, Davis E, Blough R, Golomb H, Rowley J (1986). "Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7". <i>J Clin Oncol</i> <b>4</b> (3): 325-45. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3950675" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3950675">PMID 3950675</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Clinical+and+cytogenetic+correlations+in+63+patients+with+therapy-related+myelodysplastic+syndromes+and+acute+nonlymphocytic+leukemia%3A+further+evidence+for+characteristic+abnormalities+of+chromosomes+no.+5+and+7&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=1986&amp;rft.volume=4&amp;rft.issue=3&amp;rft.au=Le+Beau+M%2C+Albain+K%2C+Larson+R%2C+Vardiman+J%2C+Davis+E%2C+Blough+R%2C+Golomb+H%2C+Rowley+J&amp;rft.pages=325-45&amp;rft_id=info:pmid/3950675">&#160;</span></li>
<li id="_note-9"><b><a href="#_ref-9" title="">^</a></b> <cite style="font-style:normal">Thirman M, Gill H, Burnett R, Mbangkollo D, McCabe N, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg A (1993). "Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations". <i>N Engl J Med</i> <b>329</b> (13): 909-14. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8361504" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8361504">PMID 8361504</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Rearrangement+of+the+MLL+gene+in+acute+lymphoblastic+and+acute+myeloid+leukemias+with+11q23+chromosomal+translocations&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1993&amp;rft.volume=329&amp;rft.issue=13&amp;rft.au=Thirman+M%2C+Gill+H%2C+Burnett+R%2C+Mbangkollo+D%2C+McCabe+N%2C+Kobayashi+H%2C+Ziemin-van+der+Poel+S%2C+Kaneko+Y%2C+Morgan+R%2C+Sandberg+A&amp;rft.pages=909-14&amp;rft_id=info:pmid/8361504">&#160;</span></li>
<li id="_note-10"><b><a href="#_ref-10" title="">^</a></b> <cite style="font-style:normal">Bizzozero O, Johnson K, Ciocco A (1966). "Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time". <i>N Engl J Med</i> <b>274</b> (20): 1095-101. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5932020" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5932020">PMID 5932020</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Radiation-related+leukemia+in+Hiroshima+and+Nagasaki%2C+1946-1964.+I.+Distribution%2C+incidence+and+appearance+time&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1966&amp;rft.volume=274&amp;rft.issue=20&amp;rft.au=Bizzozero+O%2C+Johnson+K%2C+Ciocco+A&amp;rft.pages=1095-101&amp;rft_id=info:pmid/5932020">&#160;</span></li>
<li id="_note-11"><b><a href="#_ref-11" title="">^</a></b> <cite style="font-style:normal">Yoshinaga S, Mabuchi K, Sigurdson A, Doody M, Ron E (2004). "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". <i>Radiology</i> <b>233</b> (2): 313-21. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15375227" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15375227">PMID 15375227</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Cancer+risks+among+radiologists+and+radiologic+technologists%3A+review+of+epidemiologic+studies&amp;rft.title=Radiology&amp;rft.jtitle=Radiology&amp;rft.date=2004&amp;rft.volume=233&amp;rft.issue=2&amp;rft.au=Yoshinaga+S%2C+Mabuchi+K%2C+Sigurdson+A%2C+Doody+M%2C+Ron+E&amp;rft.pages=313-21&amp;rft_id=info:pmid/15375227">&#160;</span></li>
<li id="_note-12"><b><a href="#_ref-12" title="">^</a></b> <cite style="font-style:normal">Austin H, Delzell E, Cole P (1988). "Benzene and leukemia. A review of the literature and a risk assessment.". <i>Am J Epidemiol</i> <b>127</b> (3): 419-39. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3277397" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3277397">PMID 3277397</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Benzene+and+leukemia.+A+review+of+the+literature+and+a+risk+assessment.&amp;rft.title=Am+J+Epidemiol&amp;rft.jtitle=Am+J+Epidemiol&amp;rft.date=1988&amp;rft.volume=127&amp;rft.issue=3&amp;rft.au=Austin+H%2C+Delzell+E%2C+Cole+P&amp;rft.pages=419-39&amp;rft_id=info:pmid/3277397">&#160;</span></li>
<li id="_note-13"><b><a href="#_ref-13" title="">^</a></b> Linet, MS. The Leukemias: Epidemiologic Aspects. Oxford University Press, New York 1985.</li>
<li id="_note-14"><b><a href="#_ref-14" title="">^</a></b> <cite style="font-style:normal">Evans D, Steward J (1972). "Down's syndrome and leukaemia". <i>Lancet</i> <b>2</b> (7790): 1322. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4117858" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4117858">PMID 4117858</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Down%27s+syndrome+and+leukaemia&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.date=1972&amp;rft.volume=2&amp;rft.issue=7790&amp;rft.au=Evans+D%2C+Steward+J&amp;rft.pages=1322&amp;rft_id=info:pmid/4117858">&#160;</span></li>
<li id="_note-15"><b><a href="#_ref-15" title="">^</a></b> Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leukemias. <i>Haematologica</i> 84:937, 1999. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10509043" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10509043">PMID 10509043</a></li>
<li id="_note-16"><b><a href="#_ref-16" title="">^</a></b> Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001 [erratum appears in CA Cancer J Clin 2001 Mar-Apr;51(2):144]. <i>CA Cancer J Clin</i> 2001;51:15–36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11577478" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11577478">PMID 11577478</a></li>
<li id="_note-17"><b><a href="#_ref-17" title="">^</a></b> Linet MS: The leukemias: Epidemiologic aspects. In Lilienfeld AM (ed): Monographs in Epidemiology and Biostatistics. New York, Oxford University Press, 1985, p I.</li>
<li id="_note-18"><b><a href="#_ref-18" title="">^</a></b> Aoki K, Kurihars M, Hayakawa N, et al: Death Rates for Malignant Neoplasms for Selected Sites by Sex and Five-Year Age Group in 33 Countries 1953–57 to 1983–87. Nagoya, Japan, University of Nagoya Press, International Union Against Cancer, 1992.</li>
<li id="_note-19"><b><a href="#_ref-19" title="">^</a></b> Bhatia S, Neglia JP: Epidemiology of childhood acute myelogenous leukemia. <i>J Pediatr Hematol Oncol</i> 17:94, 1995. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7749772" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7749772">PMID 7749772</a></li>
<li id="_note-20"><b><a href="#_ref-20" title="">^</a></b> Taylor GM, Birch JM: The hereditary basis of human leukemia. In Henderson ES, Lister TA, Greaves MF (eds): Leukemia, 6th ed. Philadelphia, WB Saunders, 1996, p 210.</li>
<li id="_note-21"><b><a href="#_ref-21" title="">^</a></b> Horwitz M, Goode EL, Jarvik GP: Anticipation in familial leukemia. <i>Am J Hum Genet</i> 59:990, 1996. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8900225" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8900225">PMID 8900225</a></li>
<li id="_note-22"><b><a href="#_ref-22" title="">^</a></b> Crittenden LB: An interpretation of familial aggregation based on multiple genetic and environmental factors. <i>Ann N Y Acad Sci</i> 91:764, 1978. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13696504" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13696504">PMID 13696504</a></li>
<li id="_note-23"><b><a href="#_ref-23" title="">^</a></b> Horowitz M: The genetics of familial leukemia. Leukemia 11:1345, 1997</li>
<li id="_note-24"><b><a href="#_ref-24" title="">^</a></b> Gunz FW, Veale AM: Leukemia in close relatives: Accident or predisposition. <i>J Natl Cancer Inst</i> 42:517, 1969. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4180615" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4180615">PMID 4180615</a></li>
<li id="_note-25"><b><a href="#_ref-25" title="">^</a></b> Fialkow PJ: Clonal origin of human tumors. <i>Biochim Biophys Acta</i> 1976;458:283–321. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1067873" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1067873">PMID 1067873</a></li>
<li id="_note-26"><b><a href="#_ref-26" title="">^</a></b> Fialkow PJ, Janssen JW, Bartram CR: Clonal remissions in acute nonlymphocytic leukemia: Evidence for a multistep pathogenesis of the malignancy. <i>Blood</i> 1991;77:1415–1517. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2009365" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2009365">PMID 2009365</a></li>
<li id="_note-27"><b><a href="#_ref-27" title="">^</a></b> Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. <i>Nat Med</i> 1997;3:730–737. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9212098" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9212098">PMID 9212098</a></li>
<li id="_note-28"><b><a href="#_ref-28" title="">^</a></b> Abeloff, Martin et al. (2004), pp. 2831–32.</li>
<li id="_note-29"><b><a href="#_ref-29" title="">^</a></b> Greer, John P., et al. <i>Wintrobe's Clinical Hematology</i>, 11th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2004. p. 2045–2062</li>
<li id="_note-30"><b><a href="#_ref-30" title="">^</a></b> Melnick A, Licht JD. Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. <i>Blood</i> 1999;93:3167-3215. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233871" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233871">PMID 10233871</a></li>
<li id="_note-31"><b><a href="#_ref-31" title="">^</a></b> Abeloff, Martin et al. (2004), p. 2828.</li>
<li id="_note-32"><b><a href="#_ref-32" title="">^</a></b> Abeloff, Martin et al. (2004), p. 2834.</li>
<li id="_note-33"><b><a href="#_ref-33" title="">^</a></b> Abeloff, Martin et al. (2004), p. 2835.</li>
<li id="_note-34"><b><a href="#_ref-34" title="">^</a></b> <cite style="font-style:normal">Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J, Lister T, Bloomfield C (1999). "The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997". <i>Ann Oncol</i> <b>10</b> (12): 1419-32. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10643532" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10643532">PMID 10643532</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=The+World+Health+Organization+classification+of+neoplastic+diseases+of+the+hematopoietic+and+lymphoid+tissues.+Report+of+the+Clinical+Advisory+Committee+meeting%2C+Airlie+House%2C+Virginia%2C+November%2C+1997&amp;rft.title=Ann+Oncol&amp;rft.jtitle=Ann+Oncol&amp;rft.date=1999&amp;rft.volume=10&amp;rft.issue=12&amp;rft.au=Harris+N%2C+Jaffe+E%2C+Diebold+J%2C+Flandrin+G%2C+Muller-Hermelink+H%2C+Vardiman+J%2C+Lister+T%2C+Bloomfield+C&amp;rft.pages=1419-32&amp;rft_id=info:pmid/10643532">&#160;</span></li>
<li id="_note-35"><b><a href="#_ref-35" title="">^</a></b> <cite style="font-style:normal">Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E (1996). "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party.". <i>Br J Haematol</i> <b>94</b> (3): 557-73. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8790159" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8790159">PMID 8790159</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Establishing+the+presence+of+the+t%2815%3B17%29+in+suspected+acute+promyelocytic+leukaemia%3A+cytogenetic%2C+molecular+and+PML+immunofluorescence+assessment+of+patients+entered+into+the+M.R.C.+ATRA+trial.+M.R.C.+Adult+Leukaemia+Working+Party.&amp;rft.title=Br+J+Haematol&amp;rft.jtitle=Br+J+Haematol&amp;rft.date=1996&amp;rft.volume=94&amp;rft.issue=3&amp;rft.au=Grimwade+D%2C+Howe+K%2C+Langabeer+S%2C+Davies+L%2C+Oliver+F%2C+Walker+H%2C+Swirsky+D%2C+Wheatley+K%2C+Goldstone+A%2C+Burnett+A%2C+Solomon+E&amp;rft.pages=557-73&amp;rft_id=info:pmid/8790159">&#160;</span></li>
<li id="_note-36"><b><a href="#_ref-36" title="">^</a></b> <cite style="font-style:normal">Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C (1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". <i>Br J Haematol</i> <b>33</b> (4): 451-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=188440" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=188440">PMID 188440</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Proposals+for+the+classification+of+the+acute+leukaemias.+French-American-British+%28FAB%29+co-operative+group&amp;rft.title=Br+J+Haematol&amp;rft.jtitle=Br+J+Haematol&amp;rft.date=1976&amp;rft.volume=33&amp;rft.issue=4&amp;rft.au=Bennett+J%2C+Catovsky+D%2C+Daniel+M%2C+Flandrin+G%2C+Galton+D%2C+Gralnick+H%2C+Sultan+C&amp;rft.pages=451-8&amp;rft_id=info:pmid/188440">&#160;</span></li>
<li id="_note-37"><b><a href="#_ref-37" title="">^</a></b> <cite style="font-style:normal">Vardiman J, Harris N, Brunning R (2002). "The World Health Organization (WHO) classification of the myeloid neoplasms". <i>Blood</i> <b>100</b> (7): 2292-302. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12239137" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12239137">PMID 12239137</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=The+World+Health+Organization+%28WHO%29+classification+of+the+myeloid+neoplasms&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2002&amp;rft.volume=100&amp;rft.issue=7&amp;rft.au=Vardiman+J%2C+Harris+N%2C+Brunning+R&amp;rft.pages=2292-302&amp;rft_id=info:pmid/12239137">&#160;</span> <i><a href="http://www.bloodjournal.org/cgi/content/full/100/7/2292" class="external text" title="http://www.bloodjournal.org/cgi/content/full/100/7/2292" rel="nofollow">Full text</a></i>.</li>
<li id="_note-prog"><b><a href="#_ref-prog_0" title="">^</a></b> <cite style="font-style:normal">Estey E (2001). "Prognostic factors in acute myelogenous leukemia". <i>Leukemia</i> <b>15</b> (4): 670-2. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11368376" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11368376">PMID 11368376</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Prognostic+factors+in+acute+myelogenous+leukemia&amp;rft.title=Leukemia&amp;rft.jtitle=Leukemia&amp;rft.date=2001&amp;rft.volume=15&amp;rft.issue=4&amp;rft.au=Estey+E&amp;rft.pages=670-2&amp;rft_id=info:pmid/11368376">&#160;</span></li>
<li id="_note-38"><b><a href="#_ref-38" title="">^</a></b> <cite style="font-style:normal">Wheatley K, Burnett A, Goldstone A, Gray R, Hann I, Harrison C, Rees J, Stevens R, Walker H (1999). "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.". <i>Br J Haematol</i> <b>107</b> (1): 69-79. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10520026" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10520026">PMID 10520026</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+simple%2C+robust%2C+validated+and+highly+predictive+index+for+the+determination+of+risk-directed+therapy+in+acute+myeloid+leukaemia+derived+from+the+MRC+AML+10+trial.+United+Kingdom+Medical+Research+Council%27s+Adult+and+Childhood+Leukaemia+Working+Parties.&amp;rft.title=Br+J+Haematol&amp;rft.jtitle=Br+J+Haematol&amp;rft.date=1999&amp;rft.volume=107&amp;rft.issue=1&amp;rft.au=Wheatley+K%2C+Burnett+A%2C+Goldstone+A%2C+Gray+R%2C+Hann+I%2C+Harrison+C%2C+Rees+J%2C+Stevens+R%2C+Walker+H&amp;rft.pages=69-79&amp;rft_id=info:pmid/10520026">&#160;</span></li>
<li id="_note-39"><b><a href="#_ref-39" title="">^</a></b> <cite style="font-style:normal">Slovak M, Kopecky K, Cassileth P, Harrington D, Theil K, Mohamed A, Paietta E, Willman C, Head D, Rowe J, Forman S, Appelbaum F (2000). "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.". <i>Blood</i> <b>96</b> (13): 4075-83. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11110676" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11110676">PMID 11110676</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Karyotypic+analysis+predicts+outcome+of+preremission+and+postremission+therapy+in+adult+acute+myeloid+leukemia%3A+a+Southwest+Oncology+Group%2FEastern+Cooperative+Oncology+Group+Study.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2000&amp;rft.volume=96&amp;rft.issue=13&amp;rft.au=Slovak+M%2C+Kopecky+K%2C+Cassileth+P%2C+Harrington+D%2C+Theil+K%2C+Mohamed+A%2C+Paietta+E%2C+Willman+C%2C+Head+D%2C+Rowe+J%2C+Forman+S%2C+Appelbaum+F&amp;rft.pages=4075-83&amp;rft_id=info:pmid/11110676">&#160;</span></li>
<li id="_note-40"><b><a href="#_ref-40" title="">^</a></b> <cite style="font-style:normal">Byrd J, Mrózek K, Dodge R, Carroll A, Edwards C, Arthur D, Pettenati M, Patil S, Rao K, Watson M, Koduru P, Moore J, Stone R, Mayer R, Feldman E, Davey F, Schiffer C, Larson R, Bloomfield C (2002). "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).". <i>Blood</i> <b>100</b> (13): 4325-36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393746" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393746">PMID 12393746</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2002&amp;rft.volume=100&amp;rft.issue=13&amp;rft.au=Byrd+J%2C+Mr%C3%B3zek+K%2C+Dodge+R%2C+Carroll+A%2C+Edwards+C%2C+Arthur+D%2C+Pettenati+M%2C+Patil+S%2C+Rao+K%2C+Watson+M%2C+Koduru+P%2C+Moore+J%2C+Stone+R%2C+Mayer+R%2C+Feldman+E%2C+Davey+F%2C+Schiffer+C%2C+Larson+R%2C+Bloomfield+C&amp;rft.pages=4325-36&amp;rft_id=info:pmid/12393746">&#160;</span></li>
<li id="_note-41"><b><a href="#_ref-41" title="">^</a></b> Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998 Oct 1;92(7):2322-33.</li>
<li id="_note-42"><b><a href="#_ref-42" title="">^</a></b> Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000 Dec 15;96(13):4075-83.</li>
<li id="_note-43"><b><a href="#_ref-43" title="">^</a></b> <cite style="font-style:normal">Byrd J, Mrózek K, Dodge R, Carroll A, Edwards C, Arthur D, Pettenati M, Patil S, Rao K, Watson M, Koduru P, Moore J, Stone R, Mayer R, Feldman E, Davey F, Schiffer C, Larson R, Bloomfield C (2002). "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).". <i>Blood</i> <b>100</b> (13): 4325-36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393746" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12393746">PMID 12393746</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2002&amp;rft.volume=100&amp;rft.issue=13&amp;rft.au=Byrd+J%2C+Mr%C3%B3zek+K%2C+Dodge+R%2C+Carroll+A%2C+Edwards+C%2C+Arthur+D%2C+Pettenati+M%2C+Patil+S%2C+Rao+K%2C+Watson+M%2C+Koduru+P%2C+Moore+J%2C+Stone+R%2C+Mayer+R%2C+Feldman+E%2C+Davey+F%2C+Schiffer+C%2C+Larson+R%2C+Bloomfield+C&amp;rft.pages=4325-36&amp;rft_id=info:pmid/12393746">&#160;</span></li>
<li id="_note-44"><b><a href="#_ref-44" title="">^</a></b> <cite style="font-style:normal">Thirman M, Larson R (1996). "Therapy-related myeloid leukemia.". <i>Hematol Oncol Clin North Am</i> <b>10</b> (2): 293-320. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8707757" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8707757">PMID 8707757</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Therapy-related+myeloid+leukemia.&amp;rft.title=Hematol+Oncol+Clin+North+Am&amp;rft.jtitle=Hematol+Oncol+Clin+North+Am&amp;rft.date=1996&amp;rft.volume=10&amp;rft.issue=2&amp;rft.au=Thirman+M%2C+Larson+R&amp;rft.pages=293-320&amp;rft_id=info:pmid/8707757">&#160;</span></li>
<li id="_note-45"><b><a href="#_ref-45" title="">^</a></b> <cite style="font-style:normal">Rowley J, Golomb H, Vardiman J (1981). "Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.". <i>Blood</i> <b>58</b> (4): 759-67. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7272506" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7272506">PMID 7272506</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Nonrandom+chromosome+abnormalities+in+acute+leukemia+and+dysmyelopoietic+syndromes+in+patients+with+previously+treated+malignant+disease.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=1981&amp;rft.volume=58&amp;rft.issue=4&amp;rft.au=Rowley+J%2C+Golomb+H%2C+Vardiman+J&amp;rft.pages=759-67&amp;rft_id=info:pmid/7272506">&#160;</span></li>
<li id="_note-46"><b><a href="#_ref-46" title="">^</a></b> <cite style="font-style:normal">Pedersen-Bjergaard J, Andersen M, Christiansen D, Nerlov C (2002). "Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.". <i>Blood</i> <b>99</b> (6): 1909-12. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11877259" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11877259">PMID 11877259</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Genetic+pathways+in+therapy-related+myelodysplasia+and+acute+myeloid+leukemia.&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2002&amp;rft.volume=99&amp;rft.issue=6&amp;rft.au=Pedersen-Bjergaard+J%2C+Andersen+M%2C+Christiansen+D%2C+Nerlov+C&amp;rft.pages=1909-12&amp;rft_id=info:pmid/11877259">&#160;</span></li>
<li id="_note-47"><b><a href="#_ref-47" title="">^</a></b> <cite style="font-style:normal">Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig W, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland M, Büchner T, Hiddemann W (2003). "Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.". <i>J Clin Oncol</i> <b>21</b> (2): 256–65. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12525517" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12525517">PMID 12525517</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Morphologic+dysplasia+in+de+novo+acute+myeloid+leukemia+%28AML%29+is+related+to+unfavorable+cytogenetics+but+has+no+independent+prognostic+relevance+under+the+conditions+of+intensive+induction+therapy%3A+results+of+a+multiparameter+analysis+from+the+German+AML+Cooperative+Group+studies.&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=2003&amp;rft.volume=21&amp;rft.issue=2&amp;rft.au=Haferlach+T%2C+Schoch+C%2C+L%C3%B6ffler+H%2C+Gassmann+W%2C+Kern+W%2C+Schnittger+S%2C+Fonatsch+C%2C+Ludwig+W%2C+Wuchter+C%2C+Schlegelberger+B%2C+Staib+P%2C+Reichle+A%2C+Kubica+U%2C+Eimermacher+H%2C+Balleisen+L%2C+Gr%C3%BCneisen+A%2C+Haase+D%2C+Aul+C%2C+Karow+J%2C+Lengfelder+E%2C+W%C3%B6rmann+B%2C+Heinecke+A%2C+Sauerland+M%2C+B%C3%BCchner+T%2C+Hiddemann+W&amp;rft.pages=256%E2%80%9365&amp;rft_id=info:pmid/12525517">&#160;</span></li>
<li id="_note-48"><b><a href="#_ref-48" title="">^</a></b> <cite style="font-style:normal">Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland C, Serve H, Büchner T, Haferlach T, Hiddemann W (2002). "Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease". <i>Blood</i> <b>100</b> (1): 59-66. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12070009" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12070009">PMID 12070009</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Analysis+of+FLT3+length+mutations+in+1003+patients+with+acute+myeloid+leukemia%3A+correlation+to+cytogenetics%2C+FAB+subtype%2C+and+prognosis+in+the+AMLCG+study+and+usefulness+as+a+marker+for+the+detection+of+minimal+residual+disease&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2002&amp;rft.volume=100&amp;rft.issue=1&amp;rft.au=Schnittger+S%2C+Schoch+C%2C+Dugas+M%2C+Kern+W%2C+Staib+P%2C+Wuchter+C%2C+L%C3%B6ffler+H%2C+Sauerland+C%2C+Serve+H%2C+B%C3%BCchner+T%2C+Haferlach+T%2C+Hiddemann+W&amp;rft.pages=59-66&amp;rft_id=info:pmid/12070009">&#160;</span></li>
<li id="_note-49"><b><a href="#_ref-49" title="">^</a></b> <cite style="font-style:normal">Gale R, Hills R, Kottaridis P, Srirangan S, Wheatley K, Burnett A, Linch D (2005). "No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials". <i>Blood</i> <b>106</b> (10): 3658-65. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16076872" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16076872">PMID 16076872</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=No+evidence+that+FLT3+status+should+be+considered+as+an+indicator+for+transplantation+in+acute+myeloid+leukemia+%28AML%29%3A+an+analysis+of+1135+patients%2C+excluding+acute+promyelocytic+leukemia%2C+from+the+UK+MRC+AML10+and+12+trials&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2005&amp;rft.volume=106&amp;rft.issue=10&amp;rft.au=Gale+R%2C+Hills+R%2C+Kottaridis+P%2C+Srirangan+S%2C+Wheatley+K%2C+Burnett+A%2C+Linch+D&amp;rft.pages=3658-65&amp;rft_id=info:pmid/16076872">&#160;</span></li>
<li id="_note-50"><b><a href="#_ref-50" title="">^</a></b> <cite style="font-style:normal">Paschka P, Marcucci G, Ruppert A, Mrózek K, Chen H, Kittles R, Vukosavljevic T, Perrotti D, Vardiman J, Carroll A, Kolitz J, Larson R, Bloomfield C (2006). "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study". <i>J Clin Oncol</i> <b>24</b> (24): 3904-11. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16921041" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16921041">PMID 16921041</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Adverse+prognostic+significance+of+KIT+mutations+in+adult+acute+myeloid+leukemia+with+inv%2816%29+and+t%288%3B21%29%3A+a+Cancer+and+Leukemia+Group+B+Study&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=2006&amp;rft.volume=24&amp;rft.issue=24&amp;rft.au=Paschka+P%2C+Marcucci+G%2C+Ruppert+A%2C+Mr%C3%B3zek+K%2C+Chen+H%2C+Kittles+R%2C+Vukosavljevic+T%2C+Perrotti+D%2C+Vardiman+J%2C+Carroll+A%2C+Kolitz+J%2C+Larson+R%2C+Bloomfield+C&amp;rft.pages=3904-11&amp;rft_id=info:pmid/16921041">&#160;</span></li>
<li id="_note-51"><b><a href="#_ref-51" title="">^</a></b> <cite style="font-style:normal">Cassileth P, Harrington D, Appelbaum F, Lazarus H, Rowe J, Paietta E, Willman C, Hurd D, Bennett J, Blume K, Head D, Wiernik P (1998). "Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.". <i>N Engl J Med</i> <b>339</b> (23): 1649-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9834301" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9834301">PMID 9834301</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Chemotherapy+compared+with+autologous+or+allogeneic+bone+marrow+transplantation+in+the+management+of+acute+myeloid+leukemia+in+first+remission.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1998&amp;rft.volume=339&amp;rft.issue=23&amp;rft.au=Cassileth+P%2C+Harrington+D%2C+Appelbaum+F%2C+Lazarus+H%2C+Rowe+J%2C+Paietta+E%2C+Willman+C%2C+Hurd+D%2C+Bennett+J%2C+Blume+K%2C+Head+D%2C+Wiernik+P&amp;rft.pages=1649-56&amp;rft_id=info:pmid/9834301">&#160;</span></li>
<li id="_note-52"><b><a href="#_ref-52" title="">^</a></b> <cite style="font-style:normal">Matthews J, Bishop J, Young G, Juneja S, Lowenthal R, Garson O, Cobcroft R, Dodds A, Enno A, Gillett E, Hermann R, Joshua D, Ma D, Szer J, Taylor K, Wolf M, Bradstock K (2001). "Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.". <i>Br J Haematol</i> <b>113</b> (3): 727-36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11380464" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11380464">PMID 11380464</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Patterns+of+failure+with+increasing+intensification+of+induction+chemotherapy+for+acute+myeloid+leukaemia.&amp;rft.title=Br+J+Haematol&amp;rft.jtitle=Br+J+Haematol&amp;rft.date=2001&amp;rft.volume=113&amp;rft.issue=3&amp;rft.au=Matthews+J%2C+Bishop+J%2C+Young+G%2C+Juneja+S%2C+Lowenthal+R%2C+Garson+O%2C+Cobcroft+R%2C+Dodds+A%2C+Enno+A%2C+Gillett+E%2C+Hermann+R%2C+Joshua+D%2C+Ma+D%2C+Szer+J%2C+Taylor+K%2C+Wolf+M%2C+Bradstock+K&amp;rft.pages=727-36&amp;rft_id=info:pmid/11380464">&#160;</span></li>
<li id="_note-53"><b><a href="#_ref-53" title="">^</a></b> <cite style="font-style:normal">Sanz M, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González J, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti M, Ribera J, Mandelli F (2000). "Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups". <i>Blood</i> <b>96</b> (4): 1247-53. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10942364" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10942364">PMID 10942364</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Definition+of+relapse+risk+and+role+of+nonanthracycline+drugs+for+consolidation+in+patients+with+acute+promyelocytic+leukemia%3A+a+joint+study+of+the+PETHEMA+and+GIMEMA+cooperative+groups&amp;rft.title=Blood&amp;rft.jtitle=Blood&amp;rft.date=2000&amp;rft.volume=96&amp;rft.issue=4&amp;rft.au=Sanz+M%2C+Lo+Coco+F%2C+Mart%C3%ADn+G%2C+Avvisati+G%2C+Ray%C3%B3n+C%2C+Barbui+T%2C+D%C3%ADaz-Mediavilla+J%2C+Fioritoni+G%2C+Gonz%C3%A1lez+J%2C+Liso+V%2C+Esteve+J%2C+Ferrara+F%2C+Bolufer+P%2C+Bernasconi+C%2C+Gonzalez+M%2C+Rodeghiero+F%2C+Colomer+D%2C+Petti+M%2C+Ribera+J%2C+Mandelli+F&amp;rft.pages=1247-53&amp;rft_id=info:pmid/10942364">&#160;</span></li>
<li id="_note-treatment">^ <a href="#_ref-treatment_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-treatment_1" title=""><sup><i><b>b</b></i></sup></a> Abeloff, Martin et al. (2004), pp. 2835–39.</li>
<li id="_note-54"><b><a href="#_ref-54" title="">^</a></b> Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. <i>Blood</i> 1996;88:2841–2851. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8874180" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8874180">PMID 8874180</a></li>
<li id="_note-55"><b><a href="#_ref-55" title="">^</a></b> Bishop JF, Matthews JP, Young GA, et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. <i>Blood</i> 1996;87:1710–1717. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8634416" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8634416">PMID 8634416</a></li>
<li id="_note-56"><b><a href="#_ref-56" title="">^</a></b> <cite style="font-style:normal">Bishop J (1997). "The treatment of adult acute myeloid leukemia". <i>Semin Oncol</i> <b>24</b> (1): 57-69. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9045305" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9045305">PMID 9045305</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=The+treatment+of+adult+acute+myeloid+leukemia&amp;rft.title=Semin+Oncol&amp;rft.jtitle=Semin+Oncol&amp;rft.date=1997&amp;rft.volume=24&amp;rft.issue=1&amp;rft.au=Bishop+J&amp;rft.pages=57-69&amp;rft_id=info:pmid/9045305">&#160;</span></li>
<li id="_note-57"><b><a href="#_ref-57" title="">^</a></b> Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. <i>Blood</i> 1988;72:567–572. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3165295" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3165295">PMID 3165295</a></li>
<li id="_note-58"><b><a href="#_ref-58" title="">^</a></b> Tallman MS, Anderson JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. <i>N Engl J Med</i> 1997;337:1021–1028. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9321529" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9321529">PMID 9321529</a></li>
<li id="_note-59"><b><a href="#_ref-59" title="">^</a></b> Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. <i>Blood</i> 1999;94:1192–1200. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10438706" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10438706">PMID 10438706</a></li>
<li id="_note-60"><b><a href="#_ref-60" title="">^</a></b> <cite style="font-style:normal">Estey E (2002). "Treatment of acute myelogenous leukemia". <i>Oncology (Williston Park)</i> <b>16</b> (3): 343-52, 355-6; discussion 357, 362, 365-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15046392" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15046392">PMID 15046392</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Treatment+of+acute+myelogenous+leukemia&amp;rft.title=Oncology+%28Williston+Park%29&amp;rft.jtitle=Oncology+%28Williston+Park%29&amp;rft.date=2002&amp;rft.volume=16&amp;rft.issue=3&amp;rft.au=Estey+E&amp;rft.pages=343-52%2C+355-6%3B+discussion+357%2C+362%2C+365-6&amp;rft_id=info:pmid/15046392">&#160;</span></li>
<li id="_note-61"><b><a href="#_ref-61" title="">^</a></b> <cite style="font-style:normal">Cassileth P, Harrington D, Hines J, Oken M, Mazza J, McGlave P, Bennett J, O'Connell M (1988). "Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia". <i>J Clin Oncol</i> <b>6</b> (4): 583-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3282032" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3282032">PMID 3282032</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Maintenance+chemotherapy+prolongs+remission+duration+in+adult+acute+nonlymphocytic+leukemia&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=1988&amp;rft.volume=6&amp;rft.issue=4&amp;rft.au=Cassileth+P%2C+Harrington+D%2C+Hines+J%2C+Oken+M%2C+Mazza+J%2C+McGlave+P%2C+Bennett+J%2C+O%27Connell+M&amp;rft.pages=583-7&amp;rft_id=info:pmid/3282032">&#160;</span></li>
<li id="_note-62"><b><a href="#_ref-62" title="">^</a></b> Cassileth PA, Hines JD, Oken MM, et al: Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. <i>J Clin Oncol</i> 1988;6(4):583–587. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3282032" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3282032">PMID 3282032</a></li>
<li id="_note-63"><b><a href="#_ref-63" title="">^</a></b> Mayer RJ, Davis RB, Schiffer CA, et al: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. <i>N Engl J Med</i> 1994;331:896–903. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8078551" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8078551">PMID 8078551</a></li>
<li id="_note-nccn">^ <a href="#_ref-nccn_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-nccn_1" title=""><sup><i><b>b</b></i></sup></a> O'Donnell MR, Appelbaum FR, Baer MR, et al: NCCN practice guidelines for acute myelogenous leukemia. <i>Oncology NCCN Proc</i> 2000;14:53–61. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11195419" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11195419">PMID 11195419</a></li>
<li id="_note-relapse"><b><a href="#_ref-relapse_0" title="">^</a></b> Abeloff, Martin et al. (2004), pp. 2840–41.</li>
<li id="_note-64"><b><a href="#_ref-64" title="">^</a></b> Appelbaum FR: Who should be transplanted for AML? [editorial]. <i>Leukemia</i> 2001;15:680–682. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11368380" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11368380">PMID 11368380</a></li>
<li id="_note-65"><b><a href="#_ref-65" title="">^</a></b> Appelbaum FR: Hematopoietic cell transplantation beyond first remission [keynote Address]. <i>Leukemia</i> 2002;16:157–159. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11840278" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11840278">PMID 11840278</a></li>
<li id="_note-66"><b><a href="#_ref-66" title="">^</a></b> Sievers EL, Larson RA, Stadmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>J Clin Oncol</i> 2001;19:3244–3254. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11432892" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11432892">PMID 11432892</a></li>
<li id="_note-67"><b><a href="#_ref-67" title="">^</a></b> Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. <i>J Clin Oncol</i> 2001;19:3852–3860. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11559723" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11559723">PMID 11559723</a></li>
</ol>
</div>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ul>
<li><cite class="book" style="font-style:normal">Martin Abeloff; James Armitage, John Niederhuber, Michael Kastan, W. Gillies McKenna (2004). <i>Clinical Oncology</i>, 3rd. edition, <a href="../../../s/t/_/St_Louis%2C_Missouri_31e6.html" title="St Louis, Missouri">St. Louis, Mo.</a>: <a href="../../../c/h/u/Churchill_Livingstone_597a.html" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>. <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 0-443-06629-9</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Clinical+Oncology&amp;rft.title=Clinical+Oncology&amp;rft.au=Martin+Abeloff&amp;rft.date=2004&amp;rft.edition=3rd.+edition&amp;rft.pub=%5B%5BChurchill+Livingstone%7CElsevier+Churchill+Livingstone%5D%5D&amp;rft.place=%5B%5BSt+Louis%2C+Missouri%7CSt.+Louis%2C+Mo.%5D%5D">&#160;</span></li>
</ul>
<ul>
<li><cite class="book" style="font-style:normal">Ronald Hoffman; Edward Benz, Jr., Sanford Shattil, Bruce Furie, Harvey Cohen, Leslie Silberstein, Philip McGlave (2005). <i>Hematology: Basic Principles and Practice</i>, 4th. edition, <a href="../../../s/t/_/St_Louis%2C_Missouri_31e6.html" title="St Louis, Missouri">St. Louis, Mo.</a>: <a href="../../../c/h/u/Churchill_Livingstone_597a.html" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>. <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 0-443-06629-9</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Hematology%3A+Basic+Principles+and+Practice&amp;rft.title=Hematology%3A+Basic+Principles+and+Practice&amp;rft.au=Ronald+Hoffman&amp;rft.date=2005&amp;rft.edition=4th.+edition&amp;rft.pub=%5B%5BChurchill+Livingstone%7CElsevier+Churchill+Livingstone%5D%5D&amp;rft.place=%5B%5BSt+Louis%2C+Missouri%7CSt.+Louis%2C+Mo.%5D%5D">&#160;</span></li>
</ul>
<ul>
<li><cite style="font-style:normal">Zhen-yi, Wang (2003). "Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis". <i>Hematology</i>. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14633774" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14633774">PMID 14633774</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Ham-Wasserman+Lecture%3A+Treatment+of+Acute+Leukemia+by+Inducing+Differentiation+and+Apoptosis&amp;rft.title=Hematology&amp;rft.jtitle=Hematology&amp;rft.date=2003&amp;rft.au=Zhen-yi%2C+Wang&amp;rft_id=info:pmid/14633774">&#160;</span></li>
</ul>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/u/Acute_myeloid_leukemia.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.cancer.org/docroot/lrn/lrn_0.asp" class="external text" title="http://www.cancer.org/docroot/lrn/lrn_0.asp" rel="nofollow">American Cancer Society page on Acute Myeloid Leukemia</a></li>
<li><a href="http://leukemia.acor.org/" class="external text" title="http://leukemia.acor.org/" rel="nofollow">Association of Cancer Online Resource (ACOR) Leukemia Links</a></li>
<li><a href="http://www.leukemia-lymphoma.org/all_page?item_id=8459" class="external text" title="http://www.leukemia-lymphoma.org/all_page?item_id=8459" rel="nofollow">Leukemia &amp; Lymphoma Society page on Acute Myeloid Leukemia</a></li>
<li><a href="http://www.cchs.net/health/health-info/docs/1400/1403.asp?index=6211" class="external text" title="http://www.cchs.net/health/health-info/docs/1400/1403.asp?index=6211" rel="nofollow">Childhood Acute Myeloid Leukemia</a></li>
<li><a href="http://www.marrow.org" class="external text" title="http://www.marrow.org" rel="nofollow">National Marrow Donor Program</a></li>
<li><a href="http://www.bmtinfonet.org/" class="external text" title="http://www.bmtinfonet.org/" rel="nofollow">Blood &amp; Marrow Transplant Information Network</a></li>
<li><a href="http://www.cancer.gov/cancer_information/doc.aspx?viewid=4d3f920e-87d6-4b6a-a2fe-74c6efa53398&amp;version=1" class="external text" title="http://www.cancer.gov/cancer_information/doc.aspx?viewid=4d3f920e-87d6-4b6a-a2fe-74c6efa53398&amp;version=1" rel="nofollow">National Cancer Institute (NCI) PDQ statement on AML for health professionals</a></li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../h/e/m/Template%7EHematology_42bd.html" title="Template:Hematology"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../h/e/m/Template%7EHematology_42bd.html" class="external text" title="http://en.wikipedia.org../../../h/e/m/Template%7EHematology_42bd.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><a href="../../../p/a/t/Pathology.html" title="Pathology">Pathology</a>: <a href="../../../h/e/m/Hematology.html" title="Hematology">hematology</a></b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><b><a href="../../../h/e/m/Hematological_malignancy.html" title="Hematological malignancy">Hematological malignancy</a> and <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">White blood cells</a></b><br />
<b><a href="../../../l/y/m/Lymphoid.html" title="Lymphoid">Lymphoid</a>:</b>&#160;<a href="../../../l/e/u/Leukemia.html" title="Leukemia">Lymphocytic leukemia</a>&#160;(<a href="../../../a/c/u/Acute_lymphocytic_leukemia.html" title="Acute lymphocytic leukemia">ALL</a>,&#160;<a href="../../../c/h/r/Chronic_lymphocytic_leukemia.html" title="Chronic lymphocytic leukemia">CLL</a>,&#160;<a href="../../../h/a/i/Hairy_cell_leukemia.html" title="Hairy cell leukemia">HCL</a>)&#160;• <a href="../../../l/y/m/Lymphoma.html" title="Lymphoma">Lymphoma</a>&#160;(<a href="../../../h/o/d/Hodgkin%27s_disease.html" title="Hodgkin's disease">Hodgkin's&#160;disease</a>,&#160;<a href="../../../n/o/n/Non-Hodgkin%27s_lymphoma_21ba.html" title="Non-Hodgkin's lymphoma">NHL</a>)&#160;• <a href="../../../l/y/m/Lymphoproliferative_disorders.html" title="Lymphoproliferative disorders">LPD</a>&#160;• <a href="../../../m/y/e/Myeloma.html" title="Myeloma">Myeloma</a>&#160;(<a href="../../../m/u/l/Multiple_myeloma.html" title="Multiple myeloma">Multiple&#160;myeloma</a>,&#160;<a href="../../../e/x/t/Extramedullary_plasmacytoma.html" title="Extramedullary plasmacytoma">Extramedullary plasmacytoma</a>)</p>
<p><b><a href="../../../m/y/e/Myeloid.html" title="Myeloid">Myeloid</a>:</b>&#160;<a href="../../../l/e/u/Leukemia.html" title="Leukemia">Myelogenous leukemia</a>&#160;(<a href="../../../a/c/u/Acute_myelogenous_leukemia.html" title="Acute myelogenous leukemia">AML</a>,&#160;<a href="../../../c/h/r/Chronic_myelogenous_leukemia.html" title="Chronic myelogenous leukemia">CML</a>)&#160;• <a href="../../../m/y/e/Myeloproliferative_disease.html" title="Myeloproliferative disease">MPD</a>&#160;(<a href="../../../e/s/s/Essential_thrombocytosis.html" title="Essential thrombocytosis">Essential&#160;thrombocytosis</a>,&#160;<a href="../../../p/o/l/Polycythemia.html" title="Polycythemia">Polycythemia</a>)&#160;• <a href="../../../m/y/e/Myelodysplastic_syndrome.html" title="Myelodysplastic syndrome">MDS</a>&#160;• <a href="../../../m/y/e/Myelofibrosis.html" title="Myelofibrosis">Myelofibrosis</a>&#160;• <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">Neutropenia</a></p>
<p><b><a href="../../../r/e/d/Red_blood_cell.html" title="Red blood cell">Red blood cells</a></b><br />
<a href="../../../a/n/e/Anemia.html" title="Anemia">Anemia</a>&#160;• <a href="../../../h/a/e/Haemochromatosis.html" title="Haemochromatosis">Hemochromatosis</a>&#160;• <a href="../../../s/i/c/Sickle-cell_disease.html" title="Sickle-cell disease">Sickle-cell disease</a>&#160;• <a href="../../../t/h/a/Thalassemia.html" title="Thalassemia">Thalassemia</a>&#160;• <a href="../../../h/e/m/Hemolysis.html" title="Hemolysis">Hemolysis</a>&#160;• <a href="../../../a/p/l/Aplastic_anemia.html" title="Aplastic anemia">Aplastic&#160;anemia</a>&#160;• <a href="../../../g/l/u/Glucose-6-phosphate_dehydrogenase_deficiency.html" title="Glucose-6-phosphate dehydrogenase deficiency">G6PD Deficiency</a>&#160;• <a href="../../../h/e/r/Hereditary_spherocytosis.html" title="Hereditary spherocytosis">Hereditary&#160;spherocytosis</a>&#160;• <a href="../../../h/e/r/Hereditary_elliptocytosis.html" title="Hereditary elliptocytosis">Hereditary&#160;elliptocytosis</a>&#160;• <a href="../../../h/e/m/Hemoglobinopathy.html" title="Hemoglobinopathy">Other&#160;hemoglobinopathies</a></p>
<p><b><a href="../../../c/o/a/Coagulation_of_human_blood.html" title="Coagulation of human blood">Coagulation</a> and <a href="../../../p/l/a/Platelet.html" title="Platelet">Platelets</a></b><br />
<a href="../../../t/h/r/Thrombosis.html" title="Thrombosis">Thrombosis</a>&#160;• <a href="../../../d/e/e/Deep_vein_thrombosis.html" title="Deep vein thrombosis">Deep&#160;vein&#160;thrombosis</a>&#160;• <a href="../../../p/u/l/Pulmonary_embolism.html" title="Pulmonary embolism">Pulmonary&#160;embolism</a>&#160;• <a href="../../../h/a/e/Haemophilia.html" title="Haemophilia">Hemophilia</a>&#160;• <a href="../../../i/d/i/Idiopathic_thrombocytopenic_purpura.html" title="Idiopathic thrombocytopenic purpura">ITP</a>&#160;• <a href="../../../t/h/r/Thrombotic_thrombocytopenic_purpura.html" title="Thrombotic thrombocytopenic purpura">TTP</a>&#160;• <a href="../../../d/i/s/Disseminated_intravascular_coagulation.html" title="Disseminated intravascular coagulation">DIC</a></p>
</div>
</div>
<div style="right:10px; display:none;" class="metadata topicon" id="featured-star"><map name="ImageMap_32" id="ImageMap_32">
<area href="../../../f/e/a/Wikipedia%7EFeatured_articles_569d.html" shape="rect" coords="0,0,14,14" alt="This is a featured article. Click here for more information." title="This is a featured article. Click here for more information." /></map>
<div style="position: relative;"><img src="../../../upload/6/60/LinkFA-star.png" alt="" width="14" height="14" longdesc="../../../l/i/n/Image%7ELinkFA-star.png_3c98.html" usemap="#ImageMap_32" /></div>
</div>

<!-- 
Pre-expand include size: 186708 bytes
Post-expand include size: 90911 bytes
Template argument size: 63651 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/c/u/Acute_myeloid_leukemia.html">http://en.wikipedia.org../../../a/c/u/Acute_myeloid_leukemia.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../b/l/o/Category%7EBlood_disorders_f7e0.html" title="Category:Blood disorders">Blood disorders</a></span> | <span dir='ltr'><a href="../../../h/e/m/Category%7EHematology_8cf0.html" title="Category:Hematology">Hematology</a></span> | <span dir='ltr'><a href="../../../t/y/p/Category%7ETypes_of_cancer_e9ea.html" title="Category:Types of cancer">Types of cancer</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/c/u/Acute_myeloid_leukemia.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/c/u/Talk%7EAcute_myeloid_leukemia_a355.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Acute_myeloid_leukemia">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../ar/%D8%A7/%D8%A8/%D9%8A/%D8%A7%D8%A8%D9%8A%D8%B6%D8%A7%D8%B6_%D8%A7%D9%84%D8%AF%D9%85_%D8%A7%D9%84%D9%86%D9%82%D9%88%D9%8A_%D8%A7%D9%84%D8%AD%D8%A7%D8%AF.html">العربية</a>
	      </li>
	      	      <li>
	      <a href="../../../../de/a/k/u/Akute_myeloische_Leuk%C3%A4mie_6418.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../es/l/e/u/Leucemia_mieloide_aguda.html">Español</a>
	      </li>
	      	      <li>
	      <a href="../../../../he/%D7%9C/%D7%95/%D7%A7/%D7%9C%D7%95%D7%A7%D7%9E%D7%99%D7%94_%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%90%D7%99%D7%93%D7%99%D7%AA_%D7%97%D7%A8%D7%99%D7%A4%D7%94.html">עברית</a>
	      </li>
	      	      <li>
	      <a href="../../../../ja/%E6%80%A5/%E6%80%A7/%E9%AA%A8/%E6%80%A5%E6%80%A7%E9%AA%A8%E9%AB%84%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85.html">日本語</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/l/e/u/Leucemia_Miel%C3%B3ide_Aguda_d874.html">Português</a>
	      </li>
	      	      <li>
	      <a href="../../../../sv/a/k/u/Akut_myeloisk_leukemi.html">Svenska</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 21:26, 8 April 2007 by Wikipedia user <a href="../../../a/n/t/User%7EAntibody2000_5dc7.html" title="User:Antibody2000">Antibody2000</a>. Based on work by Wikipedia user(s) <a href="../../../s/i/e/User%7ESieBot_e8dc.html" title="User:SieBot">SieBot</a>, <a href="../../../m/o/r/User%7EMortsggah_0566.html" title="User:Mortsggah">Mortsggah</a>, The Mad Genius, <a href="../../../m/a/s/User%7EMastCell_1b0e.html" title="User:MastCell">MastCell</a>, <a href="../../../h/a/r/User%7EHarryboyles_b16b.html" title="User:Harryboyles">Harryboyles</a>, <a href="../../../c/h/a/User%7EChazBeckett_1565.html" title="User:ChazBeckett">ChazBeckett</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, <a href="../../../d/r/2E/User%7EDr.michael.benjamin_a470.html" title="User:Dr.michael.benjamin">Dr.michael.benjamin</a>, <a href="../../../f/v/a/User%7EFvasconcellos_4804.html" title="User:Fvasconcellos">Fvasconcellos</a>, <a href="../../../d/r/a/User%7EDragana666_8e1b.html" title="User:Dragana666">Dragana666</a>, <a href="../../../m/i/k/User%7EMikkalai_a7bb.html" title="User:Mikkalai">Mikkalai</a>, Malolan, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, Rthrelfall, <a href="../../../b/r/a/User%7EBradBeattie_1142.html" title="User:BradBeattie">BradBeattie</a>, <a href="../../../z/i/u/User%7EZiusudra_0bde.html" title="User:Ziusudra">Ziusudra</a>, <a href="../../../a/n/t/User%7EAntiVandalBot_aa84.html" title="User:AntiVandalBot">AntiVandalBot</a>, <a href="../../../a/n/d/User%7EAndrew_Levine_ad03.html" title="User:Andrew Levine">Andrew Levine</a>, <a href="../../../d/a/n/User%7EDancingPenguin_1f97.html" title="User:DancingPenguin">DancingPenguin</a>, <a href="../../../r/a/m/User%7ERama%27s_Arrow_544a.html" title="User:Rama's Arrow">Rama's Arrow</a>, Kupos, <a href="../../../j/h/u/User%7EJHunterJ_08ee.html" title="User:JHunterJ">JHunterJ</a>, GigglesTimeTo, <a href="../../../s/a/n/User%7ESandyGeorgia_1007.html" title="User:SandyGeorgia">SandyGeorgia</a>, <a href="../../../c/h/o/User%7EChodorkovskiy_0beb.html" title="User:Chodorkovskiy">Chodorkovskiy</a>, <a href="../../../s/p/i/User%7ESpiff_4354.html" title="User:Spiff">Spiff</a>, <a href="../../../n/o/n/User%7ENoNo_4bdb.html" title="User:NoNo">NoNo</a>, BlaiseFEgan, <a href="../../../g/d/o/User%7EGdo01_992f.html" title="User:Gdo01">Gdo01</a>, <a href="../../../k/u/n/User%7EKungfuadam_b5d5.html" title="User:Kungfuadam">Kungfuadam</a>, <a href="../../../v/a/s/User%7EVashiDonsk_b026.html" title="User:VashiDonsk">VashiDonsk</a>, <a href="../../../m/a/x/User%7EMaxCosta_f8a7.html" title="User:MaxCosta">MaxCosta</a>, <a href="../../../n/i/s/User%7ENishkid64_5481.html" title="User:Nishkid64">Nishkid64</a>, Residuals, <a href="../../../s/i/r/User%7ESir_Nicholas_de_Mimsy-Porpington_81f8.html" title="User:Sir Nicholas de Mimsy-Porpington">Sir Nicholas de Mimsy-Porpington</a>, <a href="../../../r/i/n/User%7ERintrah_b987.html" title="User:Rintrah">Rintrah</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../s/c/h/User%7ESchutz_72ef.html" title="User:Schutz">Schutz</a>, <a href="../../../p/d/h/User%7EPDH_bc7b.html" title="User:PDH">PDH</a>, <a href="../../../s/p/a/User%7ESpangineer_57d1.html" title="User:Spangineer">Spangineer</a>, <a href="../../../o/u/t/User%7EOutriggr_fee9.html" title="User:Outriggr">Outriggr</a>, <a href="../../../w/a/c/User%7EWackymacs_1999.html" title="User:Wackymacs">Wackymacs</a>, <a href="../../../k/e/v/User%7EKevin_Breitenstein_8775.html" title="User:Kevin Breitenstein">Kevin Breitenstein</a>, <a href="../../../d/l/2/User%7EDl2000_b92d.html" title="User:Dl2000">Dl2000</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../t/i/m/User%7ETimVickers_d98e.html" title="User:TimVickers">TimVickers</a>, <a href="../../../n/c/u/User%7ENCurse_2986.html" title="User:NCurse">NCurse</a>, <a href="../../../c/h/a/User%7EChavoguero_6394.html" title="User:Chavoguero">Chavoguero</a>, <a href="../../../g/r/u/User%7EGrumpykansan_4648.html" title="User:Grumpykansan">Grumpykansan</a>, <a href="../../../c/l/o/User%7EClouded_de26.html" title="User:Clouded">Clouded</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../e/p/o/User%7EEpolk_d8a6.html" title="User:Epolk">Epolk</a>, Mfero, <a href="../../../p/a/p/User%7EPaperTruths_4f87.html" title="User:PaperTruths">PaperTruths</a>, <a href="../../../h/y/o/User%7EHyokano_5440.html" title="User:Hyokano">Hyokano</a>, <a href="../../../b/l/u/User%7EBluemoose_d309.html" title="User:Bluemoose">Bluemoose</a>, <a href="../../../b/r/a/User%7EBrandmeister_dd66.html" title="User:Brandmeister">Brandmeister</a>, <a href="../../../a/n/d/User%7EAndrew73_a1aa.html" title="User:Andrew73">Andrew73</a>, <a href="../../../r/o/y/User%7ERoyBoy_492a.html" title="User:RoyBoy">RoyBoy</a>, <a href="../../../f/l/a/User%7EFlatau_294a.html" title="User:Flatau">Flatau</a>, <a href="../../../j/f/u/User%7EJfurr1981_6930.html" title="User:Jfurr1981">Jfurr1981</a>, <a href="../../../a/a/r/User%7EAaron_Brenneman_d498.html" title="User:Aaron Brenneman">Aaron Brenneman</a>, <a href="../../../d/r/o/User%7EDropDeadGorgias_33d3.html" title="User:DropDeadGorgias">DropDeadGorgias</a>, <a href="../../../k/a/t/User%7EKats_494b.html" title="User:Kats">Kats</a>, <a href="../../../e/c/h/User%7EEchoray_be35.html" title="User:Echoray">Echoray</a>, <a href="../../../m/e/m/User%7EMementoVivere_56a6.html" title="User:MementoVivere">MementoVivere</a>, <a href="../../../m/i/n/User%7EMintleaf_bb08.html" title="User:Mintleaf">Mintleaf</a>, <a href="../../../b/r/i/User%7EBrim_2417.html" title="User:Brim">Brim</a>, <a href="../../../c/o/n/User%7EConti_fae9.html" title="User:Conti">Conti</a>, <a href="../../../h/a/d/User%7EHadal_a4d0.html" title="User:Hadal">Hadal</a>, Gregorio, <a href="../../../e/c/_/User%7EEC_674b.html" title="User:EC">EC</a>, <a href="../../../d/i/b/User%7EDiberri_3d04.html" title="User:Diberri">Diberri</a>, <a href="../../../e/2/3/User%7EE23_b97e.html" title="User:E23">E23</a> and <a href="../../../s/o/m/User%7ESomeone_else_bc03.html" title="User:Someone else">Someone else</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
